

## **ANNEX 1 - Terms of Reference**

To advise at the request of:

Food Standards Agency

Food Standards Scotland

Public Health England

Department of Health

Department for Business, Innovation & Skills

Department of Transport, Local Government and the Regions

Health and Safety Executive

Veterinary Medicines Directorate

Medicines and Healthcare Products Regulatory Agency

Home Office

Scottish Executive

National Assembly for Wales

Northern Ireland Assembly

Other Government Departments and Agencies

1. To assess and advise on the toxic risk to man of substances which are:

a. used or proposed to be used as food additives, or used in such a way that they might contaminate food through their use or natural occurrence in agriculture, including horticulture and veterinary practice or in the distribution, storage, preparation, processing or packaging of food;

b. used or proposed to be used or manufactured or produced in industry, agriculture, food storage or any other workplace;

c. used or proposed to be used as household goods or toilet goods and preparations;

d. used or proposed to be used as drugs, when advice is requested by the Medicines and Healthcare products Regulatory Agency;

e. used or proposed to be used or disposed of in such a way as to result in pollution of the environment.

2. To advise on important general principles or new scientific discoveries in connection with toxic risks, to co-ordinate with other bodies concerned with the assessment of toxic risks and to present recommendations for toxicity testing.

## ANNEX 2 - Code of Conduct for members of the COC/COM/COT

### Public service values

Members of the COC/COM/COT (hereafter referred to as “the Committee”) must at all times:

- observe the highest standards of **impartiality**, **integrity** and **objectivity** in relation to the advice they provide and to the management of their Committee;
- be **accountable**, through the Chair of the Food Standards Agency and the Chief Medical Officers, to Ministers, Parliament and the public for its activities and for the standard of advice it provides;
- in accordance with Government policy on **openness**, fully comply with the Freedom of Information Act 2000

The Ministers of the sponsoring departments are answerable to Parliament for the policies and performance of the Committee, including the policy framework within which it operates.

### Standards in Public Life

Members are expected to:

- comply with this Code, and ensure they understand their duties, rights and responsibilities, and that they are familiar with the function and role of their Committee and any relevant statements of Government policy. If necessary members should consider undertaking relevant training to assist them in carrying out their role;
- not misuse information gained in the course of their public service for personal gain or for political purpose, nor seek to use the opportunity of public service to promote their private interests or those of connected persons, firms, businesses or other organisations; and
- not hold any paid or high profile unpaid posts in a political party, and not engage in specific political activities on matters directly affecting the work of the Committee. When engaging in other political activities, Committee members should be conscious of their public role and exercise proper discretion. These restrictions do not apply to MPs (in those cases where MPs are eligible to be appointed), to local councillors, or to Peers in relation to their conduct in the House of Lords.
- follow the Seven Principles of Public Life set out by the Committee on Standards in Public Life (<http://www.public-standards.gov.uk/>).

### Selflessness

Holders of public office should take decisions solely in terms of the public interest. They should not do so in order to gain financial or other material benefits for themselves, their family, or their friends.

### **Integrity**

Holders of public office should not place themselves under any financial or other obligation to outside individuals or organisations that might influence them in the performance of their official duties.

### **Objectivity**

In carrying out public business, including making public appointments, awarding contracts, or recommending individuals for rewards and benefits, holders of public office should make choices on merit.

### **Accountability**

Holders of public office are accountable for their decisions and actions to the public and must submit themselves to whatever scrutiny is appropriate to their office.

### **Openness**

Holders of public office should be as open as possible about all the decisions and actions that they take. They should give reasons for their decisions and restrict information only when the wider public interest clearly demands.

### **Honesty**

Holders of public office have a duty to declare any private interests relating to their public duties and to take steps to resolve any conflicts arising in a way that protects the public interests.

### **Leadership**

Holders of public office should promote and support these principles by leadership and example.

These principles apply to all aspects of public life. The Committee has set them out here for the benefit of all who serve the public in any way.

### **Role of Members**

Members have collective responsibility for the operation of their Committee. Members are appointed as individuals to fulfil the role of their respective Committees, not as representatives of their particular profession, employer or interest group and have a duty to act in the public interest. Members are appointed on a personal basis, even when they are members of stakeholder groups and organisations. If a member declares an organisation's view rather than a personal view they should make it clear at the time of declaring that view.

Members must:

## Annual Report 2018

- engage fully in collective consideration of the issues, taking account of the full range of relevant factors, including any guidance issued by the Food Standards Agency, Health Protection Agency and the Department of Health
- undertake on appointment to comply with the Code of Practice for Scientific Advisory Committees
- not divulge any commercially sensitive information, pre-publication or unpublished research data provided to the Committee
- agree an annual report
- ensure that an appropriate response is provided to complaints and other correspondence, if necessary with reference to the sponsor department; and;
- ensure that the Committee(s) does not exceed its powers or functions.

A member's role on the Committee should not be limited by the expertise or viewpoint she or he was asked to bring to it. Any statement/report belongs to the whole Committee. Members should regard themselves free to question and comment on the information provided or the views expressed by any of the other members, even though the views or information provided do not relate to their own area of expertise.

If members believe the committee's method of working is not rigorous or thorough enough, they have the right to ask that any remaining concerns they have be put on the record. Individual members should inform the Chair (or the Secretariat on his or her behalf) if they are invited to speak in public in their capacity as a Committee member. Communications between members and the Food Standards Agency (FSA) Board, CMOs and/or Ministers will generally be through the Chair except where the Chair has agreed that an individual member should act on its behalf. Nevertheless, any member has the right of access to the FSA Board and/or the CMO on any matter that he or she believes raises important issues relating to his or her duties as a Committee member. In such cases the agreement of the rest of the Committee should normally be sought.

Committee appointments can be terminated early by either party, by giving 3 months notice, in writing. Should the Committee be disbanded before the end of the period of appointment, appointments will terminate on dissolution.

In the event that a member is found guilty of grave misconduct their appointment will be terminated immediately, in the case of the COT by the Chair of the FSA. The Department of Health has delegated the powers for appointments to the COC and COM to the NHS Appointments Commission and it will terminate appointments in consultation with the PHE/DH.

## Role of the Chair

The Chair has particular responsibility for providing effective leadership on the issues above. In addition, the Chair is responsible for:

- ensuring that the Committee meets at appropriate intervals,
- ensuring that the minutes of meetings accurately reflect proceedings and any reports to the FSA Board and/or Ministers accurately record the decisions taken
- ensuring that where appropriate, the views of individual members have been recorded;

## Annual Report 2018

- representing the views of the Committee to the general public;
- ensuring that new members are briefed on appointment (and their training needs considered), and providing an assessment of their performance, on an annual basis or when members are considered for re-appointment to the Committee or for appointment to the board of some other public body.
- providing urgent advice to the FSA and HPA on issues within the remit of the Committee, in liaison with the Secretariat,

### Role of the Deputy Chair

The Deputy Chair will assume the role of the Chair as described above if the Chair is not available.

### Role of the Secretariat

The primary function of the Secretariat is to facilitate the business of the Committee. This includes supporting the Committee by arranging its meetings, assembling and analysing information, and recording conclusions. An important task is ensuring that proceedings of the Committee are properly documented and recorded. Minutes of all Committee meetings will be taken. These will accurately reflect the proceedings and discussions that take place and will be recorded on a non-attributable basis except where the views of one or more individual members need recording (for example, when declaring an interest).

The Secretariat is also a source of advice and guidance to members on procedures and processes. The Secretariat is drawn from staff of the Food Standards Agency and Public Health England. However, it is the responsibility of the Secretariat to be an impartial and disinterested reporter and at all times to respect the Committee's independent role. The Secretariat is required to guard against introducing bias during the preparation of papers, during meetings, or in the reporting of the Committee's deliberations. Current contact details for each of the Secretariats are shown on the back page of this report.

### Role of the Assessor

Meetings of the Committee (and working groups) may be attended by Assessors. The Assessors are nominated by, and drawn from, the Agencies and Departments that sponsor the Committee, receive its advice, or have other relevant policy interests. Assessors are not members of the Committee and do not participate in Committee business in the manner of members.

The role of an Assessor is to keep their parent Department or Agency informed about the Committee's work and act as a conduit for the exchange of information. They do this by:

- advising the Committee on relevant policy developments and the implications of Committee proposals;
- informing the Committee work through the provision of information
- being informed by the Committee on matters of mutual interest.
- sharing with the Secretariat the responsibility of ensuring that information is not needlessly withheld from the Committee. Assessors should make the Committee aware of the existence of any information that has been withheld from the Committee on the basis

that it is exempt from disclosure under Freedom of Information legislation unless that legislation provides a basis for not doing so.

- ensuring that their parent Department or Agency is promptly informed of any matters which may require a response from Government.

### **Role of other Officials, Invited Experts and Contractors**

Officials from Government Departments (not departmental assessors), Regulatory Agencies and Devolved Administrations may be called upon to advise the Committee on relevant developments in order to help the Committee formulate its advice. Invited experts and contractors may also bring particular technical expertise, which may be requested by the Committee on some occasions. In the event of an official, invited expert or contractor not being able to attend written submissions may be sent via the Secretariat.

### **Role of Observers**

Members of the public and other interested parties may attend meetings as observers. However, they should not attempt to participate in Committee discussions. If an interested party wishes to provide information relevant to a topic for consideration by the Committee, they should be submitted in writing to the Secretariat at **least** seven(7) working days before the meeting. The Secretariat will discuss with the Chair the most appropriate way to present the information to the committee and the Chair's decision will be final.

Observers who have submitted information in advance of the meeting **may** be invited to provide further explanation or to make brief comments at the discretion of the Chair. Observers and/or organisations must not interfere in the work of the Secretariat or input from invited experts, contractors, officials from Government Departments and Agencies in any way which, in the view of the Chair, constitutes harassment and/or might hinder the work of the Committee. Observers and/or organisations must allow other observers and other interested parties to attend items free from interference before, during and after a meeting.

Observers and/or organisations are required to respect the work of the Committee. The Committee's discussions represent the development of its view and any comments made in developing the agreed Committee view should not be attributed to individuals. Where a subject will be considered over several meetings, observers are asked to maintain the confidentiality of the discussion until an agreed Committee opinion is finalised. The Committee's conclusions are not finalised until completion of any necessary consultation and publication of a statement or report.

Under no circumstances will Observers be permitted to record Committee proceedings, on the basis that this might inhibit free discussion. The published minutes of the meeting would provide a record of the proceedings.

Failure to observe this code of conduct may lead to exclusion of individual observers and/or organisations from meetings of the Committee.

**All observers and/or organisations are requested to read follow the Committees Openness policy (Annex 3)**

## Declaration of Members' Interests

### Definitions

In this Code, 'the industry' means:

- Companies, partnerships or individuals who are involved with the production, manufacture, sale or supply of products subject to the following legislation;  
General Food Regulations 2004  
The Food Safety Act 1990 (Amendment) Regulations 2004  
The Medicines Acts 1968 and 1971, 1981, 1986 & 2003  
The Food and Environmental Protection Act 1985  
The Consumer Protection Act 1987  
The Cosmetic (Safety) (Amendment) Regulations 2008  
Registration, Evaluation, Authorisation and Restriction of Chemicals (EC1970/2006)
- Trade associations representing companies involved with such products;
- Companies, partnerships or individuals who are directly concerned with research, development or marketing of a product which is being considered by the Committees on Toxicity, Mutagenicity, or Carcinogenicity of Chemicals in Food, Consumer Products and the Environment.
- 'the Secretariat' means the Secretariat of the COC, COM and COT;
- 'the Agency' means either the Food Standards Agency or the Health Protection Agency; and
- references to "member(s)" includes the Chair.

### Different types of Interest

The following is intended as a guide to the kinds of interests which should be declared. Where members are uncertain as to whether an interest should be declared, they should seek guidance from the Secretariat or, where it may concern a particular product which is to be considered at a meeting, from the Chair at that meeting.

*If members have interests not specified in these notes but which they believe could be regarded as influencing their advice they should declare them.*

However, neither the members nor the Secretariat are under any obligation to search out links of which they might *reasonably* not be aware. This Code suggests that interests of close family members are declared, members have in the past limited such declarations to personal partners, parents, children (minor and adult), brothers, sisters and the personal partners of any of these with the emphasis on disclosure only where the interest may, or may be perceived (by a reasonable member of the public) to influence a members' judgement.

The Secretariat is required to publish an up-to-date register of members' interests and these can be found on the relevant Committees website.

### Personal Interests

A personal interest involves the member personally. The main examples are:

- **Consultancies and/or direct employment:** any consultancy, directorship, position in or work for industry which attracts regular or occasional payments in cash or kind;
- **Fee-Paid Work:** any work commissioned by industry for which the member is paid in cash or kind;
- **Shareholdings:** any shareholding in or other beneficial interest in shares of industry. This does not include shareholdings through unit trusts or similar arrangements where the member has no influence on financial management;
- **Membership or Affiliation:** any membership role or affiliation that you or a close family member has to clubs or organisations with an interest or involvement in the work of the Agency.

### Non-Personal Interests

A non-personal interest involves payment which benefits the organisation in which the member works, but is not received by the member personally. The main examples are:

- **Fellowships:** the holding of a fellowship endowed by industry;
- **Support by Industry:** any payment, other support or sponsorship which does not convey any pecuniary or material benefit to a member personally, but which does benefit their position or organisation, e.g.
  - i) a grant for the running of a unit or department for which the member is responsible;
  - ii) a grant or fellowship or other payment to sponsor a post or a member of staff or a post graduate research programme for which the member is responsible. This does not include financial assistance for students;
  - iii) the commissioning of research or other work by, or advice from, staff who work in a unit for which the member is responsible.

Members are under no obligation to seek out knowledge of work done for, or on behalf of, the industry or other relevant bodies by departments in which they work, if they would not normally expect to be informed.

- **Trusteeships:** where a member is a trustee of a charity with investments in industry, the Secretariat can agree with the member a general declaration to cover this interest rather than draw up a detailed portfolio.

At meetings members are required to declare relevant interests and to state whether they are personal or non-personal interests and whether they are specific or nonspecific to the matter, product or substance under consideration.

### Specific Interests

A member must declare a *personal specific* interest if they have at any time worked on a matter, product or substance under consideration and have personally received payment for that work, in any form.

A member must declare a *non-personal specific* interest if they are aware that the organisation in which they work has at any time worked on the matter, product or substance under consideration but they have not personally received payment for that work, in any form.

### Non-specific Interests



A member must declare a *personal non-specific* interest if they have a **current** personal interest in a company concerned with a matter, product or substance under consideration, which does not relate specifically to the matter, product or substance under discussion. A member must declare a *non-personal non-specific* interest if they are aware that the organisation in which they work is **currently** receiving payment from the company concerned which does not relate specifically to the matter, product or substance under discussion.

If a member is aware that a substance, product or matter under consideration is or may become a competitor of a substance, product or matter manufactured, sold or supplied by a company in which the member has a *current personal* interest, they should declare their interest in the company marketing the rival product, substance or matter.

### Handling conflicts of interests

The purpose of these provisions is to avoid any danger of Committee members being influenced, or appearing to be influenced, by their private interests in the exercise of their public duties. All members should declare any personal or business interest which may, or may be *perceived* (by a reasonable member of the public) to, influence their judgement. A guide to the types of interest that should be declared is mentioned above.

#### (i) Declaration of Interests to the Secretariat

Members are required to inform the Agency in writing prior to appointment of their *current personal and non-personal* interests, including the principal position(s) held. Members are not required to disclose the amount of any salary, fee, shareholding, grant etc. An interest is current if the member has an on-going financial involvement e.g. if he or she holds shares in industry, has a consultancy contract, or if they or the organisation for which they are responsible is in the process of carrying out work for the industry.

Following appointment members are asked to inform the Secretariat at the time of any change in their *personal* interests. However, the Secretariat will contact each member on an annual basis to update their declaration of interests. Changes in *non-personal* interests can be reported annually, and those involving less than £1000 from a particular company in the previous year need not be declared. The register of interests is kept up-to-date and open to the public via the website.

#### (ii) Declaration of Interest at Meetings

Members of the Committee are required to verbally declare any direct interests relating to salaried employment or consultancies, or those of close family members in matters under discussion at each meeting, and if items are taken by correspondence between meetings. The declaration should note whether the interest is *personal or nonpersonal*, whether it is *specific* to the item under discussion, or *non-specific* and whether it is current or lapsed. Having fully explained the nature of their interest the Chair will, decide whether and to what extent the member should participate in the discussion and determination of the issue and it should be recorded in the minutes of the meeting.

### Withdrawal from meetings

If a declaration of interest has been made and the Committee decides that the member should not participate in the discussion and should withdraw from the meeting (even if held in public) and it should be recorded in the minutes of the meeting. The Chair may first allow them to make a statement on the item under discussion.

### Personal liability of Committee members

The Department of Health has a formal statement of indemnity for its advisory committee members, which includes the COC and COM, its guidance is taken from the Cabinet Office “Model Code of Practice for Board Members of Advisory Non-Departmental Public Bodies” and states that “*Legal proceedings by a third party against individual board members of advisory bodies are very exceptional. A board member may be personally liable if he or she makes a fraudulent or negligent statement which result in a loss to a third party; or may commit a breach of confidence under common law or criminal offence under insider dealing legislation, if he or she misuses information gained through their position. However, the Government has indicated that individual board members who have acted honestly, reasonably, in good faith and without negligence will not have to meet out of their own personal resources any personal civil liability which is incurred in execution or purported execution of their board functions. Board members who need further advice should consult the sponsor department.*”<sup>9</sup> except where the person has acted recklessly.

The FSA has also drawn up a formal statement of indemnity for its advisory committee members.

#### **INDEMNITY BY THE FOOD STANDARDS AGENCY TO MEMBERS OF THE COMMITTEE ON TOXICITY OF CHEMICALS IN FOOD, CONSUMER PRODUCTS AND THE ENVIRONMENT**

Food Standards Agency hereby undertakes with the members (including the Chair) of the Committee on Toxicity of Chemicals in food, Consumer products and the environment (COT) to indemnify them against all liability in respect of any action or claim which may be brought, or threatened to be brought, against them either individually or collectively by reason of or in connection with the performance of their duties as members, including all costs, charges and expenses which the Members may properly and reasonably suffer or incur in disputing any such action or claim.

The Members shall as soon as practicable notify the Food Standards Agency if any action or claim is brought or threatened to be brought against them in respect of which indemnity may be sought and if an action or claim is brought, the Food Standards Agency shall be entitled to take conduct of the defence, dispute, compromise or appeal of the action or claim and of any incidental negotiations relating to the action or claim.

The Food Standards Agency shall notify the Members as soon as practicable if it intends to so take conduct and the Members shall then provide to the Food Standards Agency such information and assistance as it shall reasonably request, subject to all out of pocket expenses properly and reasonably incurred by them being reasonably reimbursed. The Food Standards Agency shall, to the extent reasonable and practicable, consult with and keep the Members informed as and when reasonably requested by the Members in respect of any action or claim. If the Food Standards Agency does not so take conduct the Members

## Annual Report 2018

shall keep the Food Standards Agency fully informed of the progress of the action or claim and any consequent legal proceedings and consult with the Food Standards Agency as and when required by the Food Standards Agency concerning the action or claim.

The indemnity shall not extend to any losses, claims, damages, costs, charges, expenses and any other liabilities:

- (a) in respect of which the Members are indemnified by or through any defence organisation or insurers or;
- (b) which may result from bad faith (including dishonesty), wilful default or recklessness on the part of the Members; or
- (c) which may result from any of the following circumstances:
  - (i) any settlement made or compromise effected without the knowledge or consent of the Food Standards Agency on behalf of the Members of any action or claim brought, or threatened to be brought, against the Members; or
  - (ii) any admission by the Members of any liability or responsibility in respect of any action or claim brought, or threatened to be brought, against them; or
  - (iii) Members taking action that they were aware, or ought reasonably to have been aware, might prejudice the successful defence of any action or claim, once the Members had become aware that such an action or claim had been brought or was likely to be brought.

## ANNEX 3 – Openness

### Introduction

1. The Committee on Toxicity (COT) and its sister committees the Committee on Mutagenicity (COM) and Committee on Carcinogenicity (COC) are non-statutory independent scientific advisory committees which advise the Chair of the Food Standards Agency and the Chief Medical Officers (for England, Scotland, Wales and Northern Ireland) and, through them, the Government on a wide range of matters concerning chemicals in food, consumer products and the environment.

2. The Government is committed to make the operation of scientific advisory committees such as the COT/COM/COC hereafter referred to as “the Committee” more open and to increase accountability. The Committee is aware that the disclosure of information that is of a confidential nature and is communicated in circumstances importing an obligation of confidence is subject to the common law of confidentiality. There are some circumstances making disclosure of confidential information lawful for example, where the individual to whom the information relates has consented; where disclosure is in the public interest; and where there is a legal duty to do so. However, guidance is set out in the Freedom of Information Act 2000<sup>11</sup> which gives any person legal rights of access to information which is held by a public authority.

3. The Committee has agreed to hold open meetings as standard practice. Interest groups, consumer organisations etc can attend (subject to the appropriate procedures for handling commercially sensitive information and research not in the public domain, paragraphs 9-15 refer).

4. The Committee appoints lay/public interest member(s) to help to increase public scrutiny of Committee business.

5. The Committee has agreed to the publication of agendas, draft and finalised minutes, discussion papers and statements on the internet.

6. Statements will summarise all the relevant data, such as information regarding potential hazards/risks for human health in respect of the use of products and chemicals, and any recommendations for further research.

7. The Committee will be asked for an opinion based on the data available at the time of consideration. It is recognised that, for many chemicals, the toxicological information is incomplete and that recommendations for further research to address these gaps may form part of the Committee's advice

8. The release of documents (papers, minutes and statements) where the Committee has agreed an opinion on the available unpublished data but where further additional information is required in order to finalise the Committee's conclusions, needs to be considered on a case-by case basis. The relevant considerations include the likelihood that such additional data would alter the Committee's conclusion, any representations made by a company about, for example, commercial harm that early disclosure could cause and also the public interest in disclosure.

## Procedures for handling commercially sensitive information and research data not in the public domain

### Background

9. The Committee operates on a presumption of openness. However, it is recognised that the nature of the work will at times provide the Committee access to information that is not in the public domain. Decisions on confidentiality will be exercised consistently with consideration to the Freedom of Information Act 2000 and Environmental Information Regulations 2004.

10. Where there is a need to discuss matters that cannot be put in the public domain the Committee may hold a discussion in “Reserved Business”. These items will be generally discussed either at the beginning or the end of an open meeting. It is expected that such cases will be infrequent and only in clearly justified circumstances. For the most part this comprises information which is commercially sensitive such as product formulations/specifications, methods of manufacture, and reports of toxicological investigations and company evaluations and safety assessment. It would also include pre-publication or unpublished research data.

11. “Reserved Business” items will be clearly indicated as such. The Committee will advise its reasons for withholding any information, and, if possible, an indication of when and where the information withheld may be published. Information subject to such restriction, including reserved sections of the minutes will be placed in the public domain as soon as practicable should the restrictions cease to apply at a later date.

12. Normal procedure is to publish a summary of the Committee's advice on their respective websites, in the Annual Report and where necessary to ask companies to release full copies of submitted reports for retention by the British Library at the completion of a review. Given the clear Ministerial commitment to the publication of detailed information regarding the activities of advisory committees, and in particular following the assessment of products which are already available to the general public, the Committee will publish statements via the Internet soon after they have been finalised.

13. Except in cases where there is legislation under which information has been submitted and which deals with disclosure and non-disclosure, the general principle of the common law duty of confidentiality will apply. This means that any information which is commercially sensitive, pre-publication or unpublished research data and has been obtained in circumstances importing a duty of confidence may not be disclosed unless consent has been given or there is an overriding public interest in disclosure (such as the prevention of harm to others).

14. The following procedure will be adopted which allows commercially sensitive information to be identified, assessed and appropriate statements to be drafted and published on the basis of a prior mutual understanding with the companies. There is scope for companies to make representations also after submission of the information and prior to publication regarding the commercial sensitivity of data supplied and to comment on the text of statements which are to be published. However, companies would not have a right of veto in respect of such statements.

### *Procedures prior to committee consideration*

#### *Initial discussions*

15. Upon referral to Committee the Secretariat will liaise with the relevant company supplying the product in the UK to:

- i) clearly state the policy of Committee openness (summarised above)
- ii) identify and request the information needed by the Committee (e.g. test reports, publications etc).

#### *Commercially sensitive information*

iii) The company will be asked to clearly identify any commercially sensitive information and the reason for confidentiality.

#### *Pre-publication and unpublished research data*

iv) The Committee and Secretariat will respect the confidentiality of authors of (unpublished or pre-publication) research data.

#### *Handling confidential data*

v) The procedures by which the Committee will handle commercially sensitive information, pre-publication or unpublished research data and the public availability of papers, minutes, conclusions and statements where reference is made to such data will be discussed with the company or author prior to submission of papers to the Committee and is outlined in paragraphs 9-15 above. Companies will be informed that confidential annexes to Committee papers (e.g. where detailed information supplied in confidence such as individual patient information and full study reports of toxicological studies) will not be disclosed but that other information will be disclosed unless agreed otherwise with an individual company.

vi) The following is a suggested list of information which **may** be disclosed in Committee documents (papers, minutes and statements). The list is not exhaustive and is presented as a guide:

- a) name of product (or substance/chemical under consideration),
- b) information on physico-chemical properties,
- c) methods of rendering harmless,
- d) a summary of the results and evaluation of the results of tests to establish harmlessness to humans,
- e) methods of analysis,
- f) first aid and medical treatment to be given in the case of injury to persons,
- g) surveillance data (e.g. monitoring for levels in food, air, or water).

### *Procedures during and after Committee consideration*

vii) The timing of release of Committee documents (papers, minutes and statements) where the item of business involved the consideration of confidential data would be

subject to the general provisions outlined in paragraphs 9-15 above. Documents would not be released until the Committee statement is available.

viii) The most important outcome of the Committee consideration is likely to be the agreed statement. Companies will be given an opportunity to comment on the statement prior to publication and to make representations (for example, as to commercial sensitivities in the statement). The Chair would be asked to consider any comments provided, but companies would not be able to veto the publication of a statement or any part of it. Companies will continue to be asked to release full copies of submitted reports for retention by the British Library at the completion of a review.

### **Dissenting views**

16. The Committee should not seek consensus at the risk of failing to recognise different views on a subject. Any significant diversity of opinion among the members of the Committee that cannot be resolved should be accurately reflected in the minutes or report. Committee decisions should always include an explanation of where differences of opinion have arisen during discussions, specifically where there are unresolved issues and why conclusions have been reached. If however member(s) feel they cannot support the Committee conclusions they may declare a 'minority report' identifying which member(s) are making the minority report and setting out their position.

### **COC/COM/COT papers**

17. Committee papers are available on the respective website. Papers will not include commercially sensitive documents, pre-publication, unpublished or material in the public domain. Where possible a cover page with weblinks (current at the time) will be provided.

### **Remuneration and Committee finance**

18. In the financial year 2016/17 the budget for the COT, excluding Secretariat resources was £37,000. Costs were met by the Food Standards Agency (FSA).

19. Committee members may claim a fee for Committee meetings:

COC and COM Committee Chair £198 per day

COC and COM Committee Member £153 per day

COT Committee Chair £205 per day

COT Committee Member £160 per day

Where COT members are unable to attend a meeting but contribute in writing, a £50.00 reading fee is paid.

#### Review of fee rates

20. Fees in respect of the COT are set by the FSA and for COC and COM by the Department of Health. The FSA will review and revise COT rates every 2 years with the intention that rates should rise in line with the recommendations of the Senior Salaries Review Board with regard to pay in the Senior Civil Service. The FSA will also take into account comparisons with rates paid in similar advisory bodies in the UK.

## Annual Report 2018

### Travel and other expenses

21. Committee members are entitled to reimbursement of reasonable travel and subsistence expenses necessarily incurred on official committee business. Members must seek value for money and are encouraged to use the most cost effective and environmentally sustainable options for travel and accommodation.

### Working Groups

22. The Committee may establish Working Groups to consider particular topics in depth or to make brief assessments of particular issues and advise the main Committee on the possible need for further action. Such Groups contain a number of Committee members (supplemented, as necessary, by external expertise in the particular subject being considered). A Committee Chair will play a leading role in deciding which Committee members should be invited to join such groups, which may meet on a number of occasions in a particular year. Committee members may claim an allowance for participating on a Working Group.

### Terms and conditions of appointment

23. Appointments of members may be staggered so that only a proportion retire or are re-appointed each year, to help ensure continuity. (Note: The COC/COM/COT Chairs are *ex officio* members of General Advisory Committee on Science (GACS) for the term of their appointment as the COC/COM/COT Chair. COC and COM Chairs are *ex officio* members of each other's Committees.)

24. COC and COM members are usually expected to attend 3 meetings in a year. COT members are expected to attend 7 meetings in a year. Members should allow appropriate preparation time. Meetings will usually be in London.

25. The COC/COM/COT Chair must also be available for a number of other activities including: attending, with the FSA Chief Scientist, the FSA Board's annual discussion of the Agency's science; engaging with the media on any high-profile relating to the Committee's work, and discussion with the Agency Chief Scientist and GACS Secretariat in planning and developing the Committee's work (including discussing and agreeing with the Agency's Chief Scientist a framework for providing assurance on the work of the Scientific Advisory Committees in providing advice to the Agency). It is expected that these additional activities might require 5-10 days input per year.

### Feedback on performance

26. The COT Chair and members are asked to provide brief feedback on their experience on the committee each year to help the Agency ensure that the Committee operates effectively and identify any areas for improvement.

27. Committee members are normally appointed for a term of 3 years (a maximum 10 years/3 terms per member). The COT uses the feedback self-assessment form as one of the tools used to determine whether or not a committee member should be reappointed at the end of their (3 year) term.



## ANNEX 4 – Good Practice Agreement for Scientific Advisory Committees

### INTRODUCTION

The Government Chief Scientific Adviser's *Guidelines on the Use of Scientific and Engineering Advice in Policy Making* set out the basic principles which government departments should follow in assembling and using scientific advice. The key elements are to:

- **identify early** the issues which need scientific and engineering advice and where **public engagement** is appropriate;
- draw on a **wide range of expert advice** sources, particularly when there is uncertainty;
- adopt an **open and transparent approach** to the scientific advisory process and publish the evidence and analysis as soon as possible;
- **explain publicly the reasons for policy decisions**, particularly when the decision appears to be inconsistent with scientific advice; and
- **work collectively** to ensure a joined-up approach throughout government to integrating scientific and engineering evidence and advice into policy making.

The *Code of Practice for Scientific Advisory Committees* and the *Principles of Scientific Advice to Government* provide more detailed guidance on the operation of scientific advisory committees (SACs) and their relationship with their sponsor Departments.

The Food Standards Agency's Board adopted a **Science Checklist** in 2006 (updated in 2012) that makes explicit the points to be considered in the preparation of policy papers and proposals dealing with science-based issues, including those which draw on advice from the SACs.

These **Good Practice Guidelines** were drawn up in 2006 by the Chairs of the independent SACs that advise the FSA based on, and complementing, the Science Checklist. They were updated in 2012 in consultation with the General Advisory Committee on Science (GACS).

The Guidelines apply to the SACs that advise the FSA and for which the FSA is sole or lead sponsor Department:

- Advisory Committee on Animal Feedingstuffs
- Advisory Committee on Microbiological Safety of Foods
- Advisory Committee on Novel Foods and Processes
- Committee on Carcinogenicity of Chemicals in Food, Consumer Products and the Environment
- Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment
- Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment
- Science Council
- Social Science Research Committee

For the SACs with a shared sponsorship the Guidelines apply formally to their advice to the FSA; they may opt to follow them also in advising other sponsor Departments.

## Annual Report 2018

All these committees share important characteristics. They:

- are independent;
- work in an open and transparent way; and
- are concerned with risk assessment and/or science governance, not with decisions about risk management.

The Guidelines relate primarily to the risk assessment process since this is the main purpose of most of the SACs. However, the SACs may, where appropriate, comment on risks associated with different risk management options, highlight any wider issues raised by their assessment that they feel should be considered (distinguishing clearly between issues on which the SAC has an expert capability and remit, and any other issues), or any evidence gaps and/or needs for research or analysis.

In addition, GACS and SSRC may advise the FSA on aspects of the governance of risk management, or on research that relates to risk management.

Twenty-nine principles of good practice have been developed. However, the different committees have different duties and discharge those duties in different ways. Therefore, not all the principles set out below will be applicable to all of the committees, all of the time.

The SACs have agreed to review their application of the principles annually and report this in their Annual Reports. Compliance with the Guidelines will also be covered in the annual self-assessments by Members and annual feedback meetings between each SAC Chair and the FSA Chief Scientist.

## PRINCIPLES

### Defining the problem and the approach

1. The FSA will ensure that issues it asks an SAC to address are clearly defined and take account of stakeholder expectations in discussion with the SAC Secretariat and where necessary the SAC Chair. The SAC Chair will refer back to the FSA if discussion suggests that further iteration and discussion of the task is necessary. Where an SAC proposes to initiate a piece of work the SAC Chair and Secretariat will discuss this with FSA to ensure the definition and rationale for the work and its expected use by the FSA are clear.

### Seeking input

2. The Secretariat will ensure that stakeholders are consulted at appropriate points in the SAC's considerations. It will consider with the FSA whether and how stakeholder views need to be taken into account in helping to identify the issue and frame the question for the committee.
3. Wherever possible, SAC discussions should be held in public.
4. The scope of literature searches made on behalf of the SAC will be clearly set out.
5. Steps will be taken to ensure that all available and relevant scientific evidence is rigorously considered by the committee, including consulting external/additional scientific experts who may know of relevant unpublished or pre-publication data.
6. Data from stakeholders will be considered and weighted according to quality by the SAC.
7. Consideration by the Secretariat and the Chair (and where appropriate the whole SAC) will be given to whether expertise in other disciplines will be needed.
8. Consideration will be given by the Secretariat or by the SAC, in discussion with the FSA, as to whether other SACs need to be consulted.

### Validation

9. Study design, methods of measurement and the way that analysis of data has been carried out will be assessed by the SAC.
10. Data will be assessed by the committee in accordance with the relevant principles of good practice, e.g. qualitative social science data will be assessed with reference to guidance from the Government's Chief Social Researcher<sup>1</sup>.
11. Formal statistical analyses will be included wherever appropriate. To support this, each SAC will have access to advice on quantitative analysis and modelling as needed.
12. When considering what evidence needs to be collected for assessment, the following points will be considered:
  - the potential for the need for different data for different parts of the UK or the relevance to the UK situation for any data originating outside the UK; and
  - whether stakeholders can provide unpublished data.

---

<sup>1</sup> Quality in Qualitative Evaluation: A Framework for assessing research evidence [http://www.civilservice.gov.uk/wp-content/uploads/2011/09/a\\_quality\\_framework\\_tcm6-7314.pdf](http://www.civilservice.gov.uk/wp-content/uploads/2011/09/a_quality_framework_tcm6-7314.pdf); The Magenta book [http://www.hm-treasury.gov.uk/d/magenta\\_book\\_combined.pdf](http://www.hm-treasury.gov.uk/d/magenta_book_combined.pdf)

## **Annual Report 2018**

13. The list of references will make it clear which references have been subject to external peer review, and which have been peer reviewed through evaluation by the Committee, and if relevant, any that have not been peer reviewed.

### **Uncertainty**

14. When reporting outcomes, SACs will make explicit the level and type of uncertainty (both limitations on the quality of the available data and lack of knowledge) associated with their advice.
15. Any assumptions made by the SAC will be clearly spelled out, and, in reviews, previous assumptions will be challenged.
16. Data gaps will be identified and their impact on uncertainty assessed by the SAC.
17. An indication will be given by the SAC about whether the evidence base is changing or static, and if appropriate, how developments in the evidence base might affect key assumptions and conclusions.

### **Drawing conclusions**

18. The SAC will be broad-minded, acknowledging where conflicting views exist and considering whether alternative interpretations fit the same evidence.
19. Where both risks and benefits have been considered, the committee will address each with the same rigour, as far as possible; it will make clear the degree of rigour and uncertainty, and any important constraints, in reporting its conclusions.
20. SAC decisions will include an explanation of where differences of opinion have arisen during discussions, specifically where there are unresolved issues, and why conclusions have been reached. If it is not possible to reach a consensus, a minority report may be appended to the main report, setting out the differences in interpretation and conclusions, and the reasons for these, and the names of those supporting the minority report.
21. The SAC's interpretation of results, recommended actions or advice will be consistent with the quantitative and/or qualitative evidence and the degree of uncertainty associated with it.
22. SACs will make recommendations about general issues that may have relevance for other committees.

### **Communicating SACs' conclusions**

23. Conclusions will be expressed by the SAC in clear, simple terms and use the minimum caveats consistent with accuracy.
24. It will be made clear by the SAC where assessments have been based on the work of other bodies and where the SAC has started afresh and there will be a clear statement of how the current conclusions compare with previous assessments.
25. The conclusions will be supported by a statement about their robustness and the extent to which judgement has had to be used.
26. As standard practice, the SAC secretariat will publish a full set of references (including the data used as the basis for risk assessment and other SAC opinions) at as early a stage as possible to support openness and transparency of decision-making. Where this is not possible, reasons will be clearly set out, explained and a commitment made to future publication wherever possible.

## Annual Report 2018

27. The amount of material withheld by the SAC or FSA as being confidential will be kept to a minimum. Where it is not possible to release material, the reasons will be clearly set out, explained and a commitment made to future publication wherever possible.
28. Where proposals or papers being considered by the FSA Board rest on scientific evidence produced by a SAC, the Chair of the SAC (or a nominated expert member) will be invited to the table at the Open Board meetings at which the paper is discussed. To maintain appropriate separation of risk assessment and risk management processes, the role of the Chairs will be limited to providing an independent view and assurance on how their committee's advice has been reflected in the relevant policy proposals, and to answer Board Members' questions on the science. The Chairs may also, where appropriate, be invited to provide factual briefing to Board members about particular issues within their committees' remits, in advance of discussion at open Board meetings.
29. The SAC will seek (and FSA will provide) timely feedback on actions taken (or not taken) in response to the SAC's advice, and the rationale for these.

## Annex 5 – Glossary of Terms

**a priori:** The formulation of a hypothesis before undertaking an investigation or experiment.

**Absorption (biological):** Process of active or passive transport of a substance into an organism, in humans this is usually through the lungs, gastrointestinal tract or skin

**Acceptable Daily Intake (ADI):** Estimate of the amount of a substance in food or drink, expressed on a bodyweight basis (e.g. mg/kg bodyweight), that can be ingested daily over a lifetime by humans without appreciable health risk.

**Acceptable Risk:** Probability of suffering disease or injury which is considered to be sufficiently small to be “negligible”

**Acute:** Short term, in relation to exposure or effect.

**Acute reference dose (ARfD):** Estimate of the amount of a substance in food or drink, expressed on a body weight basis that can be ingested in a period of 24 hours or less without appreciable health risk.

**Acute toxicity:** Adverse effects that occur over a short period of time (up to 14 days) immediately following exposure.

**Adduct:** A chemical grouping which is covalently bound (see covalent binding) to a large molecule such as DNA (qv) or protein.

**Adenoma:** A benign neoplasm arising from a gland forming epithelial tissue such as colon, stomach or respiratory tract.

**Adverse effect:** Change in morphology, physiology, biochemistry, growth, development or lifespan of an organism which results in impairment of functional capacity or impairment of capacity to compensate for additional stress or increase in susceptibility to the harmful effects of other environmental influences.

**Aetiology:** study of causation or origination

**Ah receptor:** The Ah (Aromatic hydrocarbon) receptor protein regulates some specific gene expressions associated with toxicity. The identity of the natural endogenous chemicals which bind to the Ah receptor is unknown. Binding to the Ah receptor is an integral part of the toxicological mechanism of a range of chemicals, such as chlorinated dibenzodioxins and polychlorinated biphenyls.

**Alkylating agents:** Chemicals which leave an alkyl group covalently bound to biologically important molecules such as proteins and nucleic acids (see adduct). Many alkylating agents are mutagenic, carcinogenic and immunosuppressive.

**Allele:** Alternative form of a gene.

**Allergen:** Substance capable of stimulating an allergic reaction.

**Allergy:** The adverse health effects that may result from the stimulation of a specific immune response.

**Allergic reaction:** an adverse reaction elicited by exposure to a previously sensitised individual to the relevant antigen.

**Ames test:** *In vitro* (qv) assay for bacterial gene mutations (qv) using strains of *Salmonella typhimurium* developed by Ames and his colleagues.

**Androgen:** The generic term for any natural or synthetic compound that can interact with and activate the androgen receptor. In mammals, androgens (for example, androstenedione and testosterone) are synthesised by the adrenal glands and the testes and promote development and maintenance of male secondary sexual characteristics.

**Aneugenic:** Inducing aneuploidy (qv).

**Aneuploidy:** The circumstances in which the total number of chromosomes within a cell is not an exact multiple of the normal haploid (see 'polyploidy') number. Chromosomes may be lost or gained during cell division.

**Apoptosis:** A form of active cell death resulting in fragmentation of the cell into membrane-bound fragments (apoptotic bodies). These are usually rapidly removed *in vivo* by engulfment by phagocytic cells. Apoptosis can occur normally during development, but is often triggered by toxic stimuli.

**ARfD:** see Acute reference dose

**Base pair (bp):** Two complementary nucleotide (qv) bases joined together by chemical bonds.

**Benchmark dose (BMD) modelling:** An approach to dose-response assessment that aims to be more quantitative than the NOAEL process. This approach constructs mathematical models to fit all data points in the dose-response study and uses the best fitting model to interpolate an estimate of the dose that corresponds to a particular level of response (a benchmark response), often 10%. A measure of uncertainty is also calculated, and the lower confidence limit on the benchmark dose is called the BMDL. The BMDL accounts for the uncertainty in the estimate of the dose-response that is due to characteristics of the experimental design such as sample size. The BMDL can be used as the point of departure for derivation of a health-based guidance value or a margin of exposure.

**Bias:** In the context of epidemiological studies, an interference which at any stage of an investigation tends to produce results that depart systematically from the true values (to be distinguished from random error). The term does not necessarily carry an imputation of prejudice or any other subjective factor such as the experimenter's desire for a particular outcome.

**Bioavailability:** A term referring to the proportion of a substance which reaches the systemic circulation unchanged after a particular route of administration.

**Bioinformatics:** The science of informatics as applied to biological research. Informatics is the management and analysis of data using advanced computing techniques. Bioinformatics is particularly important as an adjunct to genomics research, because of the large amount of complex data this research generates.

**Biomarker:** Observable change (not necessarily pathological) in an organism, related to a specific exposure or effect.

**Body burden:** Total amount of a chemical present in an organism at a given time.

**Bradford Hill Criteria:** Sir Austin Bradford-Hill established criteria that may be used to assist in the interpretation of associations reported from epidemiological studies:-

- Strength – The stronger the association the more likely it is causal. The COC has previously noted that the relative risks of  $<3$  need careful assessment for effects of bias or confounding.
- Consistency – The association has been consistently identified by studies using different approaches and is also seen in different populations with exposure to the chemical under consideration.
- Specificity – Limitation of the association to specific exposure groups or to specific types of disease increases likelihood that the association is causal.
- Temporality – The association must demonstrate that exposure leads to disease.

The relationship of time since first exposure, duration of exposure and time since last exposure are all important in assessing causality.

- Biological gradient – If an association reveals a biological gradient or doseresponse curve, then this evidence is of particular importance in assessing causality.
- Plausibility – Is there appropriate data to suggest a mechanism by which exposure could lead to concern? However, even if an observed association may be new to science or medicine it should not be dismissed.
- Coherence – Cause and effect interpretation of data should not seriously conflict with generally known facts.
- Experiment – Can the association be demonstrated? Evidence from experimental animals may assist in some cases. Evidence that removal of the exposure leads to a decrease in risk may be relevant.
- Analogy – Have other closely related chemicals been associated with the disease?



**Bronchial:** Relating to the air passages conducting air from the trachea (windpipe) to the lungs.

**C. elegans:** *Caenorhabditis elegans*, a nematode or roundworm, the first animal to have its genome completely sequenced and all the genes fully characterised.

**Cancer:** Synonym for a malignant neoplasm – that is, a tumour (qv) that grows progressively, invades local tissues and spreads to distant sites (see also tumour and metastasis).

**Candidate gene:** A gene that has been implicated in causing or contributing to the development of a particular disease.

**Carcinogenesis:** The origin, causation and development of tumours (qv). The term applies to benign as well as malignant neoplasms and not just to carcinomas (qv).

**Carcinogenicity bioassay:** Tests carried out in laboratory animals, usually rats and mice, to determine whether a substance is carcinogenic. The test material is given throughout life to groups of animals at different dose levels.

**Carcinogen:** The causal agents which induce tumours. They include external factors (chemicals, physical agents, viruses) and internal factors such as hormones. Chemical carcinogens are structurally diverse and include naturally-occurring substances as well as synthetic compounds. An important distinction can be drawn between *genotoxic* (qv) carcinogens which have been shown to react with and mutate DNA, and *nongenotoxic* carcinogens which act through other mechanisms. The activity of genotoxic carcinogens can often be predicted from their chemical structure - either of the parent compound or of active metabolites (qv). Most chemical carcinogens exert their effects after prolonged exposure, show a dose-response relationship and tend to act on a limited range of susceptible target tissues. Carcinogens are sometimes species or sex-specific and the term should be qualified by the appropriate descriptive adjectives to aid clarity. Several different chemical and other carcinogens may interact, and constitutional factors (genetic susceptibility, hormonal status) may also contribute, emphasising the multifactorial nature of the carcinogenic process.

**Carcinoma:** Malignant tumour arising from epithelial cells lining, for example, the alimentary, respiratory and urogenital tracts and from epidermis, also from solid viscera such as the liver, pancreas, kidneys and some endocrine glands. (See also 'tumour').

**Case-control study:** (Synonyms - case comparison study, case referent study, retrospective study) A comparison is made of the proportion of cases who have been exposed to a particular hazard (e.g. a carcinogen) with the proportion of controls who have been exposed to the hazard.

**Cell transformation:** The process by which a normal cell acquires the capacity for neoplastic growth. Complete transformation occurs in several stages both *in vitro* and *in vivo*. One step which has been identified *in vitro* is 'immortalisation' by which a cell acquires the ability to divide indefinitely in culture. Such cells do not have the capacity to form tumours in animals, but can be induced to do so by extended passage *in vitro*, by treatment with chemicals, or by transfection with oncogene DNA. The transformed

phenotype so generated is usually, but not always, associated with the ability of the cells to grow in soft agar and to form tumours when transplanted into animals. It should be noted that each of these stages of transformation can involve multiple events which may or may not be genetic. The order in which these events take place, if they occur at all, *in vivo* is not known.

**Chromosomal aberrations:** Collective term of particular types of chromosome damage induced after exposure to exogenous chemical or physical agents which damage the DNA. (see clastogen).

**Chromosome:** In simple prokaryotic organisms, such as bacteria and most viruses, the chromosome consists of a single circular molecule of DNA containing the entire genetic material of the cell. In eukaryotic cells, the chromosomes are thread-like structures, composed mainly of DNA and protein, which are present within the nuclei of every cell. They occur in pairs, the numbers varying from one to more than 100 per nucleus in different species. Normal somatic cells in humans have 23 pairs of chromosomes, each consisting of linear sequences of DNA which are known as genes (qv).

**Chronic effect:** Consequence which develops slowly and has a long-lasting course (often but not always irreversible).

**Chronic exposure:** Continued exposures occurring over an extended period of time, or a significant fraction of the life-time of a human or test animal.

**Clastogen:** An agent that produces chromosome breaks and other structural aberrations such as translocations. Clastogens may be viruses or physical agents as well as chemicals. Clastogenic events play an important part in the development of some tumours.

**Clearance:** Volume of blood or plasma, or mass of an organ, effectively cleared of a substance by elimination (metabolism and excretion) in a given time interval. Total clearance is the sum or the clearances for each eliminating organ or tissue.

**Clone:** A term which is applied to genes, cells, or entire organisms which are derived from - and are genetically identical to - a single common ancestor gene, cell, or organism, respectively. Cloning of genes and cells to create many copies in the laboratory is a common procedure essential for biomedical research.

**Coding regions:** those parts of the DNA that contain the information needed to form proteins. Other parts of the DNA may have non-coding functions (e.g. start-stop, pointing or timer functions) or as yet unresolved functions or maybe even 'noise'.

**Codon:** a set of three nucleotide bases in a DNA or RNA sequence, which together code for a unique amino acid.

**Cohort:** A defined population that continues to exist through time.

**Cohort study:** (Synonyms - follow-up, longitudinal study) The study of a group of people defined at a particular point in time (the cohort), who have particular characteristics in common, such as a particular exposure. They are then observed over a period of time for

the occurrence of disease. The rate at which the disease develops in the cohort is compared with the rate in a comparison population, in which the characteristics (e.g. exposure) are absent.

**Complementary DNA (cDNA):** cDNA is DNA that is synthesised in the laboratory from mRNA by reverse transcription. A cDNA is so-called because its sequence is the complement of the original mRNA sequence.

**Confounding variable:** (synonym - confounder) An extraneous variable that satisfies BOTH of 2 conditions: (1) it is a risk factor for the disease under study (2) it is associated with the study exposure but is not a consequence of exposure. For example cigarette smoking is a confounding variable with respect to an association between alcohol consumption and heart disease. Failure to adjust for a confounding variable results in distortion of the apparent magnitude of the effect of the exposure under study. (In the example, smoking is a risk factor for heart disease and is associated with alcohol consumption but is not a consequence of alcohol consumption.)

**Congeners:** Related compounds varying in chemical structure but with similar biological properties.

**Covalent binding:** Chemical bonding formed by the sharing of an electron pair between two atoms. Molecules are combinations of atoms bound together by covalent bonds.

**Cytochrome P450 (CYP):** An extensive family of haem-containing proteins involved in enzymic oxidation of a wide range of endogenous and xenobiotic (qv) substances and their conversion to forms that may be more easily excreted. In some cases the metabolites produced may be reactive and may have increased toxicity. In other cases the substances may be natural precursors of hormones (e.g. steroids).

**Cytogenetic:** Concerning chromosomes, their origin, structure and function.

**Deletion:** A chromosomal aberration in which a proportion of the chromosome is lost. Deletions may range in size from a single nucleotide (qv) to an entire chromosome. Such deletions may be harmless, may result in disease, or may in rare cases be beneficial.

**DNA (Deoxyribonucleic Acid):** The carrier of genetic information for all living organisms except the group of RNA viruses. Each of the 46 chromosomes in normal human cells consists of 2 strands of DNA containing up to 100,000 nucleotides, specific sequences of which make up genes (qv). DNA itself is composed of two interwound chains of linked nucleotides (qv).

**DNA probe:** A piece of single-stranded DNA, typically labelled so that it can be detected (for example, a radioactive or fluorescent label can be used), which can single out and bind with (and only with) another specific piece of DNA. DNA probes can be used to determine which sequences are present in a given length of DNA or which genes are present in a sample of DNA.

**DNA repair genes:** Genes which code for proteins that correct damage in DNA sequences. When these genes are altered, mutations may be able to accumulate in the genome, ultimately resulting in disease.

**Dominant lethal assay:** See Dominant Lethal mutation.

**Dominant lethal mutation:** A dominant mutation that causes death of an early embryo.

**Dose:** Total amount of a substance administered to, taken or absorbed by an organism.

**Endocrine modulator** (synonym – endocrine disruptor): A chemical, which can be naturally occurring or man-made, that causes adverse health effects in an organism, as a result of changes in hormonal function.

**Endonuclease:** An enzyme that cleaves its nucleic acid substrate at internal sites in the nucleotide sequence.

**Enterohepatic circulation:** Cyclical process involving intestinal re-absorption of a substance that has been excreted through bile followed by transfer back to the liver, making it available for biliary excretion again.

**Epidemiology:** Study of factors determining the causes, frequency, distribution, and control of diseases in a human population.

**Epigenetics:** Study of changes in organisms caused by modification of gene expression rather than changes to the genetic code itself.

**Epithelium:** The tissue covering the outer surface of the body, the mucous membranes and cavities of the body.

**Erythema:** Reddening of the skin due to congestion of blood or increased blood flow in the skin.

**Erythrocyte:** Red blood cell.

**Estrogen:** Sex hormone or other substance capable of developing and maintaining female characteristics of the body.

**European Food Safety Authority (EFSA):** European organisation that provides risk assessments to the European Commission

**Exogenous:** Arising outside the body.

**Exposure Assessment:** Process of measuring or estimating concentration or intensity, duration and frequency of exposure to an agent present in the environment.

**Fibrosarcoma:** A malignant tumour arising from connective tissue (see 'tumour').

**Fluorescence In-Situ Hybridisation:** A technique which allows individual chromosomes and their centromeres to be visualised in cells.

**Fetotoxic:** Causing toxic, potentially lethal effects to the developing fetus.

**Forestomach:** (See glandular stomach).

## Annual Report 2018

**Full gene sequence:** the complete order of bases in a gene. This order determines which protein a gene will produce.

**Gavage:** Administration of a liquid via a stomach tube, commonly used as a dosing method in toxicity studies.

**Gene:** The functional unit of inheritance: a specific sequence of nucleotides along the DNA molecule, forming part of a chromosome (qv).

**Gene expression:** The process by which the information in a gene is used to create proteins or polypeptides.

**Gene families:** Groups of closely related genes that make similar products.

**Gene product:** The protein or polypeptide coded for by a gene.

**Genetic engineering:** Altering the genetic material of cells or organisms in order to make them capable of making new substances or performing new functions.

**Genetic polymorphism:** a difference in DNA sequence among individuals, groups, or populations (e.g. a genetic polymorphism might give rise to blue eyes versus brown eyes, or straight hair versus curly hair). Genetic polymorphisms may be the result of chance processes, or may have been induced by external agents (such as viruses or radiation). Changes in DNA sequence which have been confirmed to be caused by external agents are generally called “mutations” rather than “polymorphisms”.

**Genetic predisposition:** susceptibility to a disease which is related to a polymorphism, which may or may not result in actual development of the disease.

**Genetically modified organism (GMO):** An organism which has had genetic material inserted into or removed from its cells.

**Genome:** All the genetic material in the chromosomes of a particular organism; its size is generally given as its total number of base pairs.

**Genomic DNA:** The basic chromosome set consisting of a species-specific number of linkage groups and the genes contained therein.

**Genomics:** The study of genes and their function.

**Genotoxic:** The ability of a substance to cause DNA damage, either directly or after metabolic activation (see also carcinogens).

**Genotype:** The particular genetic pattern seen in the DNA of an individual. “Genotype” is usually used to refer to the particular pair of alleles that an individual possesses at a certain location in the genome. Compare this with phenotype.

**Glandular stomach:** The stomach in rodents consists of two separate regions – the forestomach and the glandular stomach. Only the glandular stomach is directly comparable to the human stomach.

**Half-life:** Time in which the concentration of a substance will be reduced by half, assuming a first order elimination process.

**Hazard:** Set of inherent properties of a substance, mixture of substances or a process involving substances that make it capable of causing adverse effects to organisms or the environment.

**Hepatic:** Pertaining to the liver.

**Hepatocyte:** The principal cell type in the liver, possessing many metabolising enzymes (see 'metabolic activation').

**Hepatotoxic:** Causing toxicity to the liver.

**Horizon Scanning:** The systematic examination of potential threats, opportunities and likely future developments, which are at the margins of current thinking and planning. Horizon scanning may explore novel and unexpected issues, as well as persistent problems and trends. Overall, horizon scanning is intended to improve the robustness of policies and the evidence base

**Human Genome Project:** An international research effort aimed at discovering the full sequence of [bases](#) in the human [genome](#), led in the UK by the Wellcome Trust and Medical Research Council.

**Hyperplasia:** An increase in the size of an organ or tissue due to an increase in the number of cells.

**Hypertrophy:** An increase in the size of an organ or tissue due to an increase in the volume of individual cells within it.

**Idiosyncrasy:** Specific (and usually unexplained) reaction of an individual to e.g. a chemical exposure to which most other individuals do not react at all. General allergic reactions do not fall into this category.

**In situ hybridisation (ISH):** Use of a DNA or RNA probe to detect the presence of the complementary DNA sequence in cloned bacterial or cultured eukaryotic cells.

**In vitro:** A Latin term used to describe effects in biological material outside the living animal or plant (literally "in glass").

**In vivo:** A Latin term used to describe effects in living animals or plants (literally "in life").

**Incidence:** Number of new cases of illness occurring during a given period in a specific population.

**Inducing agent:** A chemical which, when administered to an animal, causes an increase in the expression of a particular enzyme. For example, chlorinated dibenzodioxins are inducing agents which act via the Ah-receptor (qv) to induce cytochrome P450 (qv) CYP1A1.

**Intraperitoneal:** Within the abdominal cavity.

**Isomer:** Isomers are two or more chemical compounds with the same molecular formula but having different properties owing to a different arrangement of atoms within the molecule. The  $\beta$ -isomer of alitame is formed when the compound degrades and the atoms within the molecule are rearranged.

**kilobase (kb):** A length of DNA equal to 1000 nucleotides.

**Knockout animals:** Genetically engineered animals in which one or more genes, usually present and active in the normal animal, are absent or inactive.

**LC50:** The theoretical lethal concentration for 50% of a group of organisms

**LD50:** The dose of a toxic compound that causes death in 50% of a group of experimental animals to which it is administered. It can be used to assess the acute toxicity of a compound, but is being superseded by more refined methods.

**Leukaemia:** A group of neoplastic disorders (see tumour) affecting blood-forming elements in the bone marrow, characterised by uncontrolled proliferation and disordered differentiation or maturation. Examples include the lymphocytic leukaemia's which develop from lymphoid cells and the myeloid leukaemia's which are derived from myeloid cells (producing red blood cells, mainly in bone marrow).

**Ligand:** A molecule which binds to a receptor.

**Lipids:** Fats, substances containing a fatty acid and soluble in alcohols or ether, but insoluble in water.

**Lipophilic:** 'Lipid liking' - a substance which has a tendency to partition into fatty materials.

**LOAEL:** Lowest observed adverse effect level. The lowest administered dose at which an adverse effect has been observed.

**Lymphocyte:** A type of white blood cell that plays central roles in adaptive immune responses.

**Lymphoma:** Malignant tumours arising from lymphoid tissues. They are usually multifocal, involving lymph nodes, spleen, thymus and sometimes bone marrow, and other sites outside the anatomically defined lymphoid system. (See also 'tumour').

**Malignancy:** See 'tumour'.

**Margin of exposure (MOE) approach:** A methodology that allows the comparison of the risks posed by different genotoxic and carcinogenic substances. The MOE approach uses a reference point, often taken from an animal study and corresponding to a dose that causes a low but measurable response in animals. This reference point is then compared with various dietary intake estimates in humans, taking into account differences in

consumption patterns. It is also used for contaminants for which there is insufficient information to set a Tolerable Daily Intake (qv).

**Messenger RNA (mRNA):** The DNA of a gene is transcribed (see transcription) into mRNA molecules, which then serve as a template for the synthesis of proteins.

**Meta-analysis:** In the context of epidemiology, a statistical analysis of the results from independent studies, which aims to produce a single estimate of an effect.

**Metabolic activation:** Metabolism of a compound leading to an increase in its activity, whether beneficial (e.g. activation of a pro-drug) or deleterious (e.g. activation to a toxic metabolite).

**Metabolic activation system:** A cell-free preparation (e.g. from the livers of rats pretreated

with an inducing agent (qv)) added to *in vitro* tests to mimic the metabolic activation typical of mammals.

**Metabolism:** Chemical modification of a compound by enzymes within the body, for example by reactions such as hydroxylation (see cytochrome P450), epoxidation or conjugation. Metabolism may result in activation, inactivation, accumulation or excretion of the compound.

**Metabolite:** Product formed by metabolism of a compound.

**Metabonomics:** Techniques available to identify the presence and concentrations of metabolites in a biological sample.

**Metaphase:** Stage of cell division (mitosis and meiosis) during which the chromosomes are arranged on the equator of the nuclear spindle (the collection of microtubule filaments which are responsible for the movement of chromosomes during cell division). As the chromosomes are most easily examined in metaphase, cells are arrested at this stage for microscopical examination for chromosomal aberrations (qv) - known as metaphase analysis.

**Metastasis:** The process whereby malignant cells become detached from the primary tumour mass, disseminate (mainly in the blood stream or in lymph vessels) and 'seed out' in distant sites where they form secondary or metastatic tumours. Such tumours tend to develop at specific sites and their anatomical distribution is often characteristic; it is non-random.

**µg:** Microgram

**Micronuclei:** Isolated or broken chromosome fragments which are not expelled when the nucleus is lost during cell division, but remain in the body of the cell forming micronuclei. Centromere positive micronuclei contain DNA and/or protein material derived from the centromere. The presence of centromere positive micronuclei following exposure to chemicals can be used to evaluate the aneugenic (qv) potential of chemicals.



**Micronucleus test:** See Micronuclei.

**Mitogen:** A stimulus which provokes cell division in somatic cells.

**Mitosis:** The type of cell division which occurs in somatic cells when they proliferate. Each daughter cell has the same complement of chromosomes as the parent cell.

**Mouse lymphoma assay:** An *in vitro* assay for gene mutation in mammalian cells using a mouse lymphoma cell line L5178Y, which is heterozygous for the gene (carries only one functional gene rather than a pair) for the enzyme thymidine kinase (TK<sup>+/-</sup>). Mutation of that single gene is measured by resistance to toxic trifluorothymidine. Mutant cells produce two forms of colony - large, which represent mutations within the gene and small, which represent large genetic changes in the chromosome such as chromosome aberrations. Thus this assay can provide additional information about the type of mutation which has occurred if colony size is scored.

**Mouse spot test:** An *in vivo* test for mutation, in which pregnant mice are dosed with the test compound and mutations are detected by changes (spots) in coat colour of the offspring. Mutations in the melanocytes (skin pigment cells) of the developing fetus are measured.

**Mucosal:** Regarding the mucosa or mucous membranes, consisting of epithelium (qv) containing glands secreting mucus, with underlying layers of connective tissue and muscle.

**Murine:** Often taken to mean "of the mouse", but strictly speaking means of the Family Muridae which includes rats and squirrels.

**Mutagen:** is a physical or chemical agent that changes the genetic information (usually DNA) of an organism

**Mutation:** A permanent change in the amount or structure of the genetic material in an organism or cell, which can result in a change in phenotypic characteristics. The alteration may involve a single gene, a block of genes, or a whole chromosome. Mutations involving single genes may be a consequence of effects on single DNA bases (point mutations) or of large changes, including deletions, within the gene. Changes involving whole chromosomes may be numerical or structural. A mutation in the germ cells of sexually reproducing organisms may be transmitted to the offspring, whereas a mutation that occurs in somatic cells may be transferred only to descendent daughter cells.

**Mycotoxin:** Toxic compound produced by a fungus.

**Neoplasm:** See 'tumour'.

**Neoplastic:** Abnormal cells, the growth of which is more rapid than that of other cells.

**Nephrotoxicity:** Toxicity to the kidney.

**Neurobehavioural:** Of behaviour determined by the nervous system.

**Neurotoxicity:** Toxicity to the nervous system.

**NOAEL:** No observed adverse effect level. The highest administered dose at which no adverse (qv) effect has been observed.

**Non-genotoxic:** See 'carcinogens'.

**Non-Hodgkin lymphomas:** (NHLs) are a diverse group of hematologic cancers which encompass any lymphoma other than Hodgkin's Lymphoma

**Nucleic acid:** One of the family of molecules which includes the DNA and RNA molecules. Nucleic acids were so named because they were originally discovered within the nucleus of cells, but they have since been found to exist outside the nucleus as well.

**Nucleotide:** the "building block" of nucleic acids, such as the DNA molecule. A nucleotide consists of one of four bases - adenine, guanine, cytosine, or thymine - attached to a phosphate-sugar group. In DNA the sugar group is deoxyribose, while in RNA (a DNA-related molecule which helps to translate genetic information into proteins), the sugar group is ribose, and the base uracil substitutes for thymine. Each group of three nucleotides in a gene is known as a codon. A nucleic acid is a long chain of nucleotides joined together, and therefore is sometimes referred to as a "polynucleotide."

**Null allele:** inactive form of a gene.

**Odds ratio (OR):** The odds of disease in an exposed group divided by the odds of disease in an unexposed group.

**OECD:** Organisation for Economic Cooperation and Development

**Oedema:** Excessive accumulation of fluid in body tissues.

**Oestrogen:** (See estrogen)

**Oligonucleotide:** A molecule made up of a small number of nucleotides, typically fewer than 25.

**Oncogene:** A gene which is associated with the development of cancer (see protooncogene).

**Organochlorine:** A group of chemical compounds, containing multiple chlorine atoms, that are usually of concern as environmental pollutants. Some organochlorines have been manufactured as pesticides or coolants and others arise as contaminants of manufacturing processes or incineration.

**Pharmacokinetics:** Description of the fate of drugs in the body, including a mathematical account of their absorption, distribution, metabolism and excretion (see toxicokinetics).

**Pharmacogenomics:** The science of understanding the correlation between an individual patient's genetic make-up (genotype) and their response to drug treatment. Some drugs work well in some patient populations and not as well in others. Studying the genetic basis

of patient response to therapeutics allows drug developers to design therapeutic treatments more effectively.

**Phenotype:** The observable physical, biochemical and physiological characteristics of a cell, tissue, organ or individual, as determined by its genotype and the environment in which it develops.

**Phytoestrogen:** Any plant substance or metabolite that induces biological responses in vertebrates and can mimic or modulate the actions of endogenous estrogens usually by binding to estrogen receptors.

**Plasmid:** A structure composed of DNA that is separate from the cell's genome (qv). In bacteria, plasmids confer a variety of traits and can be exchanged between individuals, even those of different species. Plasmids can be manipulated in the laboratory to deliver specific genetic sequences into a cell.

**Plasticiser:** A substance which increases the flexibility of certain plastics.

**Polymer:** A very large molecule comprising a chain of many similar or identical molecular sub units (monomers) joined together (polymerised). An example is the polymer glycogen, formed from linked molecules of the monomer glucose.

**Polymerase chain reaction (PCR):** A method for creating millions of copies of a particular segment of DNA. PCR can be used to amplify the amount of a particular DNA sequence until there are enough copies available to be detected.

**Polymorphism:** (see genetic polymorphism)

**<sup>32</sup>P postlabelling:** A sensitive experimental method designed to measure low levels of DNA adducts induced by chemical treatment.

**Prevalence:** The number of cases of a disease that are present in a population at a given time.

**Primer:** Short pre-existing polynucleotide chain to which new deoxyribonucleotides can be added by DNA polymerase.

**Proteomics:** The determination of the function of all of the proteins encoded by the organism's entire genome.

**Proto-oncogene:** One of a group of normal genes which are concerned with the control of cellular proliferation and differentiation. They can be activated in various ways to forms (oncogenes) which are closely associated with one or more steps in carcinogenesis. Activating agents include chemicals and viruses. The process of proto-oncogene activation is thought to play an important part at several stages in the development of tumours.

**Receptor:** A small, discrete protein in the cell membrane or within the cell with which specific molecules interact to initiate a change in the working of a cell.

**Recombinant DNA:** DNA molecules that have been created by combining DNA more than one source.

**Reference nutrient intake (RNI):** An amount of the nutrient that is enough, or more than enough, for most (usually at least 97%) of people in a group. If the average intake of a group is at the RNI, then the risk of deficiency in the group is very small.

**Regulatory gene:** A gene which controls the protein-synthesising activity of other genes.

**Relative risk:** A measure of the association between exposure and outcome. The rate of disease in the exposed population divided by the rate of disease among the unexposed population in a cohort study or a population-based case control study. A relative risk of 2 means that the exposed group has twice the disease risk compared to the unexposed group.

**Renal:** Relating to the kidney.

**Reporter gene:** A gene that encodes an easily assayed product that is coupled to the upstream sequence of another gene and transfected (qv) into cells. The reporter gene can then be used to see which factors activate response elements in the upstream region of the gene of interest.

**Risk:** Possibility that a harmful event (death, injury or loss) arising from exposure to a chemical or physical agent may occur under specific conditions.

**Risk Assessment:** process of evaluating a potential hazard, likelihood of suffering, or any adverse effects from certain human activities

**Risk Management:** process designed to identify, contain, reduce, or eliminate the potential for harm to the human population; usually concerned with the delivery system and site rather than performance.

**RNA (ribonucleic acid):** a molecule similar to DNA (qv), which helps in the process of decoding the genetic information carried by DNA.

**SAHSU:** Small Area Health Statistics Unit

**Safener:** A substance which reduces or eliminates the phytotoxic effects of a plant protection product on certain plant species.

**Safety:** Practical certainty that injury will not result from a hazard under defined conditions.

**SCF:** The European Commission's Scientific Committee on Food (formerly the Scientific Committee for Food). Its role has now been taken on by the European Food Safety Authority (qv).

**Single nucleotide polymorphism (SNP):** DNA sequence variations that occur when a single nucleotide in the genome sequence is altered. For example, a SNP might change the DNA sequence AAGGCTAA to ATGGCTAA. By convention, SNPs occur in at least 1% of the population.

**Sister chromatid exchange (SCE):** Exchange of genetic material between two subunits of a replicated chromosome.

**Stakeholder:** A person or organisation representing the interests and opinions of a group with an interest in the outcome of (for example) a review or policy decision.

**Suppressor gene:** A gene which helps to reverse the effects of damage to an individual's genetic material, typically effects which might lead to uncontrolled cell growth (as would occur in cancer). A suppressor gene may, for example, code for a protein which checks genes for misspellings, and/or which triggers a cell's selfdestruction if too much DNA damage has occurred.

**Surfactant:** Also called: surface-active agent. A substance, such as a detergent, that can reduce the surface tension of a liquid and thus allow it to foam or penetrate solids; a wetting agent.

**Systematic review:** A review that has been prepared using a documented systematic approach to minimising biases and random errors.

**TDI:** See 'Tolerable Daily Intake'.

**Teratogen:** A substance which, when administered to a pregnant woman or animal, can cause congenital malformations (structural defects) in the baby or offspring.

**Testicular Dysgenesis Syndrome (TDS):** The hypothesis that maldevelopment (dysgenesis) of the fetal testis results in hormonal or other malfunctions of the testicular somatic cells which in turn predispose a male to the disorders that comprise the TDS, i.e. congenital malformations (cryptorchidism and hypospadias) in babies and testis cancer and low sperm counts in young men.

**Threshold:** Dose or exposure concentration below which an effect is not expected.

**Tolerable Daily Intake (TDI):** An estimate of the amount of contaminant, expressed on a body weight basis (e.g. mg/kg bodyweight), that can be ingested daily over a lifetime without appreciable health risk.

**Toxic Equivalency Factor (TEF):** A measure of relative toxicological potency of a chemical compared to a well characterised reference compound. TEFs can be used to sum the toxicological potency of a mixture of chemicals which are all members of the same chemical class, having common structural, toxicological and biochemical properties. TEF systems have been published for the chlorinated dibenzodioxins, dibenzofurans and dioxin-like polychlorinated biphenyls, and for polycyclic aromatic hydrocarbons.

**Total Toxic Equivalent (TEQ):** Is a method of comparing the total relative toxicological potency within a sample. It is calculated as the sum of the products of the concentration of each congener multiplied by the toxic equivalency factor (TEF).

**Toxicodynamics:** The process of interaction of chemical substances with target sites and the subsequent reactions leading to adverse effects.

**Toxicogenic:** producing or capable of producing a toxin.

**Toxicogenomics:** A scientific subdiscipline that combines the emerging technologies of genomics and bioinformatics to identify and characterise mechanisms of action of known and suspected toxicants. Currently, the premier toxicogenomic tools are the DNA microarray and the DNA chip, which are used for the simultaneous monitoring of expression levels of hundreds to thousands of genes.

**Toxicokinetics:** The description of the fate of chemicals in the body, including a mathematical account of their absorption, distribution, metabolism and excretion. (see pharmacokinetics)

**Transcription:** the process during which the information in a length of DNA (qv) is used to construct an mRNA (qv) molecule.

**Transcriptomics:** Techniques available to identify mRNA from actively transcribed genes.

**Transfer RNA (tRNA):** RNA molecules which bond with amino acids and transfer them to ribosomes, where protein synthesis is completed.

**Transfection:** A process by which the genetic material carried by an individual cell is altered by incorporation of exogenous DNA into its genome.

**Transgenic:** Genetically modified to contain genetic material from another species (see also genetically modified organism).

**Transgenic animal models:** Animals which have extra (exogenous) fragments of DNA incorporated into their genomes. This may include reporter genes to assess *in-vivo* effects such as mutagenicity in transgenic mice containing a recoverable bacterial gene (*lacZ* or *lac I*). Other transgenic animals may have alterations of specific genes believed to be involved in disease processes (e.g. cancer). For example strains of mice have been bred which carry an inactivated copy of the p53 tumour suppressor gene (qv) -, or an activated form of the *ras* oncogene which may enhance their susceptibility of the mice to certain types of carcinogenic chemicals.

**Translation:** In molecular biology, the process during which the information in mRNA molecules is used to construct proteins.

**Tumour** (Synonym - neoplasm): A mass of abnormal, disorganised cells, arising from pre-existing tissue, which are characterised by excessive and uncoordinated proliferation and by abnormal differentiation. **Benign** tumours show a close morphological resemblance to their tissue of origin; grow in a slow expansile fashion; and form circumscribed and (usually) encapsulated masses. They may stop growing and they may regress. Benign tumours do not infiltrate through local tissues and they do not metastasise (qv). They are rarely fatal. **Malignant** tumours (synonym - cancer) resemble their parent tissues less closely and are composed of increasingly abnormal cells in terms of their form and function. Well differentiated examples still retain recognisable features of their tissue of origin but these characteristics are progressively lost in moderately and poorly differentiated malignancies: undifferentiated or anaplastic tumours are composed of cells which resemble no known normal tissue. Most malignant tumours grow rapidly, spread

progressively through adjacent tissues and metastasise to distant sites. Tumours are conventionally classified according to the anatomical site of the primary tumour and its microscopical appearance, rather than by cause. Some common examples of nomenclature are as follows:

- Tumours arising from epithelia (qv): benign - adenomas, papillomas; malignant - adenocarcinomas, papillary carcinomas.
- Tumours arising from connective tissues such as fat, cartilage or bone: benign - lipomas, chondromas, osteomas; malignant - fibrosarcomas, liposarcomas, chondrosarcomas, osteosarcomas.
- Tumours arising from lymphoid tissues are malignant and are called lymphomas (qv); they are often multifocal. Malignant proliferations of bone marrow cells are called leukaemias.

*Benign tumours may evolve to the corresponding malignant tumours; examples involve the adenoma → carcinoma sequence in the large bowel in humans, and the papilloma → carcinoma sequence in mouse skin.*

**Tumour initiation:** A term originally used to describe and explain observations made in laboratory models of multistage carcinogenesis, principally involving repeated applications of chemicals to the skin of mice. Initiation, in such contexts, was the first step whereby small numbers of cells were irreversibly changed, or initiated. Subsequent, separate events (see tumour promotion) resulted in the development of tumours. It is now recognised that these early, irreversible heritable changes in initiated cells were due to genotoxic damage, usually in the form of somatic mutations and the initiators used in these experimental models can be regarded as genotoxic carcinogens (qv).

**Tumour promotion:** An increasingly confusing term, originally used, like 'tumour initiation' to describe events in multistage carcinogenesis in experimental animals. In that context, promotion is regarded as the protracted process whereby initiated cells undergo clonal expansion to form overt tumours. The mechanisms of clonal expansion are diverse, but include direct stimulation of cell proliferation, repeated cycles of cell damage and cell regeneration and release of cells from normal growth-controlling mechanisms. Initiating and promoting agents were originally regarded as separate categories, but the distinction between them is becoming increasingly hard to sustain. The various modes of promotion are non-genotoxic, but it is incorrect to conclude that 'non-genotoxic carcinogen' (qv) and 'promoter' are synonymous.

**Uncertainty factor:** Value used in extrapolation from experimental animals to man (assuming that man may be more sensitive) or from selected individuals to the general population: for example, a value applied to the NOAEL to derive an ADI or TDI. The value depends on the size and type of population to be protected and the quality of the toxicological information available.

**Unscheduled DNA Synthesis (UDS):** DNA synthesis that occurs at some stage in the cell cycle other than the S period (the normal or 'scheduled' DNA synthesis period), in response to DNA damage. It is usually associated with DNA repair.

**Volume of distribution:** Apparent volume of fluid required to contain the total amount of a substance in the body at the same concentration as that present in the plasma, assuming equilibrium has been attained.

**WHO-TEQs:** The system of Toxic Equivalency Factors (TEFs) used in the UK and a number of other countries to express the concentrations of the less toxic dioxin-like compounds (16 PCDDs/PCDFs and 12 PCBs) as a concentration equivalent to the most toxic dioxin 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) is that set by the World Health Organisation (WHO), and the resulting overall concentrations are referred to as WHO-TEQs (Total toxic equivalents).

**Xenobiotic:** A chemical foreign to the biologic system.

**Xenoestrogen:** A 'foreign' compound with estrogenic activity (see estrogen).



## ANNEX 6 - Index to Subjects and Substances considered in previous annual reports of the Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment

Subject	Year	Page
Accelerator Mass Spectrometry – An aid to carcinogen risk assessment	2000	103
Acceptable Daily Intakes (ADI)	1992	15
Acetyl tributyl citrate (ATBC)	1994 1997	24 63
Acid sweets, adverse reactions to	2004	7, 25
Aclonifen	2008	227
and risk assessments of its postulated metabolites (hydroquinone and phenol), Statement on the review of mutagenicity of	2008	262
Acrylamide	1992 2007 2008 2009 2014	54 130, 137 235 139, 153 8, 44
EFSA consultation on a draft scientific opinion on acrylamide in food		
in fried and baked food	2002	7
in the diet of infants and young children	2016	7
Ad hoc Expert Group on Vitamins and Minerals (EVM)	1997	6
Additives	1991	22
and behaviour	2002	11
hyperactivity and,	2000	27
in foods especially prepared for infants and young children	1991	22
in infant formulae and follow-on formulae	1991	14
Adverse birth outcomes		
Epidemiological studies of landfill and	2007	24
Adverse Outcome Pathways, presentation on.	2017	52
Adverse trends in the development of the male reproductive system	2003	21
- potential chemical causes	2004	7, 32
Advisory Committee on Novel Foods and Processes (ACNFP)	1991	21
Agaritine	1992 1996	36, 54 34
Aircraft cabin air environment	2013	7
Air fresheners	2008	7
Air pollution, polycyclic aromatic hydrocarbons in	2004	183
Air quality guidelines: consideration of genotoxins	1992	58
Alcohol consumption and squamous cell carcinoma: review of the quantitative relationship between	2005	139

## Annual Report 2018

Alcohol and alcoholic beverages		
Mutagenicity	1995	28
Carcinogenicity	1995	46
Evaluation of sensible drinking message	1995	58
and breast cancer	2002 2003 2004	133 196 173, 194
Alcohol attributable burden of cancer	2011	56
Alcohol and cancer risk	2013 2016	58 43
Alcohol effects on the epigenome in the germline: role in the inheritance of alcohol-related pathology.	2017	53
Alitame	1992 1999 2000 2001	36 7 10 7
Alternaria toxins	1991	50
Allergenic foods, timing of introduction to the infant diet and influence on the risk of development of atopic outcomes and autoimmune disease	2016	16
maternal and infant dietary exposures and,	2017	26
Allergenic foods, COT/SACN Subgroup on the timing of introduction into the infant diet.	2017	20
Aluminium in the diet of infants and young children	2016	8
Amalgam, Dental	1997	13
Amano 90	2000 2001	15 12
Amnesic Shellfish Poisoning	2001	7
Aneuploidy		
inducing chemicals	1993	36
Thresholds for	1995 1996	37 42
ECETOC Monograph on	1997	78
Aniline	1992	40
Antimony trioxide	1997	62
Arsenic		
in diet of infants and young children	2016	10
in drinking water	1994	32
in food, opinion of the European Food Safety Authority	2009	8
In seaweed – urgent advice	2004	13, 22
Total and inorganic in food: results of the 1999 Total Diet Study	2002 2003	20 7
Asbestos	2011 2013	57 52
relative vulnerability of children to		
Ascorbyl palmitate	1991	15
Aspartame	1992 1996	12 56

## Annual Report 2018

	2006 2013	280, 287 13, 14
Assessment of the adequacy of the 10-fold uncertainty factor to allow for interspecies variation in developmental toxicity	2013	29
Astaxanthin in farmed fish	1991	15
Atypical results in the lipophilic shellfish toxin mouse bioassay	2004	8
Avoparcin	1992	56
Azodicarbonamide	1994	6
Benz(a)pyrene in drinking water	1994	35
Benzene	1991	45
induced carcinogenicity	1997	114
Consideration of evidence for a threshold	1998	32
Benzimidazoles		
Consideration of a common mechanism group	2007	130
Betal quid, pan masala and areca nut chewing	1994 2007 2008	36 179 276, 291

Biobank project	2003 2004	194 192
Biomonitoring studies for genotoxicity in pesticide applicators	2004 2005	146 82;93;111
Bisphenol A	1997	6
in canned food	2001	8
diglycidyl ether (BADGE)	1996 1997	35 8
EFSA Consultation on a draft scientific opinion on the risks to public health	2014	9
Bitter Apricot Kernels, cyanogenic glycosides in	2006	7,29
Boron in drinking water and food	1995	6
Bracken	1993 2008	33 8, 49
Breast cancer, alcohol and	2002 2003 2004	133 196 173
Organochlorine insecticides and	2004	180
consideration of the epidemiology data on dieldrin, DDT and certain hexachlorocyclohexane isomers	2004	223
Breast implants	1992 1999	58 7
Polyurethane coated	1994	36
PIP hydrogel	2000 2002	11 16
Breast milk, PCBs in	2001	19
proposal for a breastmilk analysis study using pre-existing samples held by Imperial College London.	2017	26

## Annual Report 2018

archive, toxicological evaluation of chemical analyses carried out as part of a pilot study for a	2004	14, 70
Bromate	1993	50
in bottled water – urgent advice	2004	14
Brominated flame retardants in fish from the Skerne-Tees river system	2003	8
Organic contaminants: Preliminary discussion on toxicological evaluation	2005	7
Bromine	2000	17
Bromodichloromethane	1994	22
Bromoform	1994	23, 33
1,3-Butadiene	1992 1998	41, 58 33
Butylated hydroxyanisole	1992	16
Bystander Risk Assessment Working Group (BRAWG)	2010 2012 2014	25 18 16
Recommendations of the Bystander Risk Assessment Working Group report concerning skin sensitisation from exposure to pesticides		
Cabin air environment, ill-health in aircraft crew and the possible relationship to smoke/fume events in aircraft	2006 2007	19 7, 66
Cadmium in the 2006 Total Diet Study	2009	12
Caffeine, Reproductive effects of	2001 2007 2008 2015	22 24 14, 49 7
Caffeine and alcohol: combined effects on health and behaviour	2012	7
Calcium-parathyroid hormone axis, phosphate and the.	2004	11, 54
Cancer etiology and causal inference.	2017	53
Cancer incidence near municipal solid waste incinerators		
in Great Britain	2000	104
Update review of epidemiological studies on	2008	284
Review of	2009	240
Canned foods, Bisphenol A in	2001	8
Captan	1993	35, 50
Caramel (Type 1)	1991	30
Carbaryl	1995	30, 64
Carcinogenesis		
age-related differences in susceptibility to	2006	281
mode of action and human framework relevance	2005	134
“Tissue Organisation Field Theory” of	2006	286
Carcinogenic air pollutants, Quantification of risk	2002	128
Carcinogenicity guidelines	1991	44
Carcinogenicity of		
2,3,7,8-tetrachlorodibenzo(p)dioxin (TCDD)	2001	136

## Annual Report 2018

mixtures	2008	284
	2009	228
carbon nanotubes	2010	60
Carcinogenicity studies		
in rats, Minimum duration of	2001	142
	2002	130
OECD Guidance document for the performance of chronic toxicity and	2009	225
Revision of OECD Test Guidelines for	2008	282
Carcinogenicity testing of tobacco products	2009	219
Carcinogen – DNA adducts as a biomarker for cancer risk	2008	277
Carcinogenic risk of Insulin-like growth factor-1 (IGF-1) in the diet, The potential	2009	229
Carcinogens		
COC guidance on a strategy for the risk assessment of	2004	188
Assessing the risks of acute or short-term exposure to	2007	179
Carrageenan	1991	14
	1993	12
	1997	11
Cell lines expressing human xenobiotic metabolising enzyme in mutagenicity testing	1995	38
Cell transformation assays	1994	26
COM review on cell transformation assays	2012	44
Cell Transformation Assays for the Prediction of Carcinogens	2012	37
Chemical exposure resulting from landfill sites	2009	36
Chemical mixtures	2008	229, 236
Chemicals in human milk, Persistent environmental	2009	223
Childhood cancer	2004	191
	2005	134
and paternal smoking	1997	68
Hazard proximities in Great Britain (from 1953 to 1980)	1997	110

Childhood leukaemia and residence near sources of traffic exhaust and petrol fumes: review of the possible associations between	2005	143
Children, Age as an independent risk factor for chemically-induced acute myelogenous leukaemia in	2008	276
Children Research project (T07040) investigating the effect of mixtures on certain food colours and a preservative on behaviour in	2007	8, 49
Children's Environment and Health Strategy for the UK	2008	9
Chlorinated and brominated contaminants in shellfish, farmed and wild fish	2006	10, 67
Chlorinated drinking water	1991	32

## Annual Report 2018

	1992	55
Chlorinated drinking water and cancer	2007 2008	185 278, 285
and reproductive outcomes	1998 2001 2004	8 23 8, 46
Chlorinated paraffins in food	2009	13, 111
Chlorination disinfection by-products and risk of congenital anomalies in England and Wales – new SAHSU study	2008	9
Chlorine	1993	33
Chlorine and chlorine dioxide as flour treatment agents	1996	7, 36
Chlorobenzenes	1997	12
2-Chlorobenzylidene malonitrile (CS)	1998	34
new formulation of, and PAVA (Nonivamide) sprays: combined use and CS Spray	2017 2005 2006 1999 2013	28 17 7, 21 7, 51 14
Chlorodibromomethane	1994	23
Chloroform	1994	22, 32
Chlorophenols	2011 2012	45 37
Cholangiocarcinoma in the rat	2005	155
Chromium picolinate	2003 2004	141 135, 148
Chromium VI	2015	36
Chrysotile-substitutes, Carcinogenic risks	1998	50
Chymosin	1991 2000 2002	16, 28 16 10
Classification of chemicals on the basis of mutagenic properties	1992	43
Climate change	2011	52
COC guidance on a strategy for the risk assessment of carcinogens	2004	188
COC guidelines		
Review of	2001	142
Revision of	2002	134
COC template	2002	129
COM template	2002	87
COM guidance		
CONCAWE		
Assessment of exposure to petrol vapour	2005	145
Assessment of exposure to benzene vapour	2005	146
COT/COC/COM review of toxicogenomics	2004	144, 190
Comet Assay	1995 1998	39 35

## Annual Report 2018

	2005	125
	2006	249
Comfrey	1992	19
	1994	7
<b>Committee procedures</b>		
Code of Conduct for Observers	2007	18
Code of Practice for Scientific Advisory Committees (CoPSAC)	2001	106
	2007	18
Consultation document for updating the Code of Practice for Scientific Advisory Committees	2010	23
EFSA consultation on draft guidance on biological relevance	2017	17
EFSA consultation on draft guidance on the risk assessment of substances present in food intended for infants below 16 weeks of age.	2017	19
EFSA consultation on draft guidance on weight of evidence	2017	18
EFSA opinion on statistical significance and biological relevance	2011	22
Draft EFSA protocol for a systematic review on health outcomes related to the age of introduction of complementary food for the scientific assessment of the appropriate age of introduction of complementary feeding into an infant's diet.	2017	20
Good Practice Agreement for Scientific Advisory Committees	2006	16
Horizon Scanning	2011	22
	2017	20, 42, 52
In the light of the Phillips enquiry (COC)	2001	9, 106
Open Meetings – review of procedure	2006	17
Peer review by EU-ANSA agencies	2017	20
Performance evaluation for Committee members	2006	17
Procedure for holding COT meetings in open session	2003	18
Quinquennial Review of the COT	2011	23
Reviews of risk procedures used by Government advisory Committees dealing with food (COM)	2000	22, 110
Second round of consultation	2003	12, 106
Uncertainty framework from a social science perspective	2011	25
Workshop on Social Science insights for risk assessment	2006	17
Contaminants in soil	2001	10
	2008	9
	2013	15, 54
Coumarin	1998	29, 41
Cyanogenic glycosides in apricot kernels	2006	7, 29
Cyclamate	1995	6
Cycloastragenol	2015	42

## Annual Report 2018

Dental amalgam	1997	13
Dentists and dental nurses, olfactory neuroblastomas: possible association in	2003 2004	197 179, 251
Deoxenivalenol (DON)	1991	50
Developmental Neurotoxicity	2009	14
Dibenzo(a,l)pyrene	2002	17
In air pollution	2003	189
Dibutylphthalate (DBP) in clogs	2010	9
1,3-Dichloropropan-2-ol	2003	128, 190
and 2,3-dichloropropan-1-ol	2001 2004	99, 137 137, 148
Carcinogenicity of	2004	243

Dichlorvos	2001 2002 2010 2011	99 83 61 53
Diesel exhaust	1991	47
Update on carcinogenicity from 1990	1996	62
Diet and Drug Interactions	2005	7, 27
Dietary exposure to phthalates – data from the Total Diet Study	2010 2011	27 8
Dietary restriction and carcinogenesis in rats	1991	51
Di-2-ethylhexyl adipate	1991	17, 28
Diethyl-m-toluamide (DEET)	2002 2003	8 128
update of toxicology literature	2006	8, 37
Diethylstilboestrol	1993	38
Dietary exposure to phthalates – data from the Total Diet Study	2011	8
Di-isopropyl-naphthalenes in food packaging made from recycled paper and board:	1998 2000 2002	9 14 9
Conclusion on mutagenicity studies using the mouse lymphoma assay (MLA)	2000	62
Dimethoate	1992	39
Dimethyldicarbonate	1992	24, 37
Dimetridazole	2002	84
2,4-Dinitrophenol	2003	14
Dioxin research	2008	10
Dioxins		
2,3,7,8-Tetrachlorodibenzo-p-dioxin	1993 1995 1998 1999	49 15, 64 19, 45 49
Carcinogenicity of	2001	136
Mixed halogenated	2010	14



## Annual Report 2018

Dioxins and dioxin-like PCBs		
In marine fish and fish products	1999	31
Consideration of the TDI	2000 2001	26 10
Developmental effects in rats	2007	7, 30
Dietary exposure	2000	13
in free range eggs	2000	14
in fish oil – urgent advice	2002	9
2005 WHO Toxic Equivalency Factors	2006	15, 203
Dioxins - reanalysis by EPA	2012	10
Disinfectants and disinfection by-products in prepared salads	2006	9, 61
Dithiocarbamates in latex products	1994	18
DNA adduct inducing chemicals, Joint Meeting of COM and COC on the significance of low level exposures	1996	48
DNA binding approaches	2005	125
DNA integrity in human fertility investigations	2016	34
DNA gyrase inhibitors	1992	42, 58
DNA repair at low doses, genotoxic carcinogens and	2004	136, 176
Dominant Lethal Assay	1994	26
Domoic acid in King Scallops ( <i>Pecten Maximus</i> )	2014	7
Doramectin in Lamb	2007	25
Drinking Water		
Arsenic in,	1999	59
Benz(a)pyrene in,	1994	32
Boron in,	1994	35
Chlorinated,	1991 1995	32 6
and cancer	2007 2008	185 278, 285
Reproductive outcomes of,	1992 1998	55 8
Fluoranthene in,	1994 1995	34, 70 33
Trihalomethanes in,	1994 1995	22, 32, 69 35
Early identification of non-genotoxic carcinogens	2000	106
ECETOC Monograph on Aneuploidy	1997	78
ECETOC workshop on use of T25 in chemical carcinogen evaluation	2001	141
Effects of chronic dietary exposure to methanol	2011	10
Effect of soy phytoestrogen supplementation on thyroid status and cardiovascular risk	2011	27
Electronic nicotine, or non-nicotine, delivery systems (e-cigarettes), potential toxicological risks from	2017	28
Emulsifier YN (Ammonium Phosphatides)	1994	7
Endocrine disrupting chemicals – definition for regulatory purposes	2010	11

## Annual Report 2018

Endosulfan, pentachlorobenzene and chlordecone in the infant diet	2013	18
Enrofloxacin	1992 1993	56 50
Environmental Tobacco Smoke (ETS) and lung cancer	1997 2003	88 191
Enzymes - Amano 90	2000 2001	15 12
- Chymosin	1999 2000 2002 2003	16 16 10 8
- Immobilised lipase from <i>Rhizopus niveus</i>	1994 1998	9 13
- Lipase D	2000 2001	16 12
- Newlase analytical method to detect rhizoxin	2000 2002 2004	17 11 10
- Xylanase preparation from <i>Aspergillus niger</i>	2001	13
Enzyme Submission – Newlase analytical method to detect rhizoxin	2004	10
Eosinophilia-myalgia syndrome, tryptophan and	2003 2004	21, 83 12
EPA risk assessment guideline: supplemental data for assessing susceptibility from early life exposure to carcinogens	2003	195
Epigenetics in carcinogenesis  in chemical risk assessment, in chemical risk assessment, joint committee workshop on	2013 2016 2017 2017	53 35 54 43
Epoxidised soya bean oil	1994 1999	8 16

Erythritol	2003 2004	9 9
Erythrosine	1991	29
Ethaboxam – partial review	2007	131
Ethanol, acetaldehyde and alcoholic beverages	2000	62
Ethanol intake, effects on pregnancy, reproduction and infant development	1995	8
EFSA consultation on draft guidance document on the use of the benchmark dose in risk assessment	2016	17
European Food Safety Authority (EFSA) Advice to	2005	141
Evaluation of cycloastragenol	2015	38
Evaluation of sensible drinking message	1995	58

## Annual Report 2018

Evidence for an increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1996	2000	107
Evident toxicity as an endpoint in acute toxicity testing	2007	19
Evolving approaches to chemical risk assessment	2007	23, 38
Exposure to carcinogens Single or short term	2005	140
Expression of uncertainty	2012	13
Florfenicol	1993	12
Fluoranthene in drinking water	1994 1995	34, 70 33
Fluoride	1995	35
Fluorine, bromine and iodine	2000 2002	17 89
Fluorine (fluoride): 1997 Total Diet Study	2001 2002 2003	23 19 9
Flunixin, meglumine and flunixin-meglumine	2003 2005	129 119
Folic acid	2009	222
Fortification and carcinogenesis	2006 2007	282 181
Food Colours and children's behaviour, research	2007	8
Food Surveillance Papers	1991 1992 1993	22 27 23, 48
Food additives Hyperactivity and, and behaviour and developmental toxicology	2000 2002 2005	27 11 5, 42
Food and food ingredients adverse reactions to,	2000	10
Food chemical exposure assessment	2002	12
Food Intolerance	1997 1999	17 16
Food Standards Agency funded research and surveys	2000	18
Food Standards Agency funded research on health effects of mixtures of food additives (T01040/41)	2008	10, 204
Food Standards Agency funded research project on Interpretation of Margins of Exposure for Genotoxic Carcinogens (T01051)	2013	56
Food Standards Agency review of scientific committees	2001	24
FSA-funded research and other progress on mixtures of pesticides and similar substances	2011	11
FSA-funded research on the combined effects of aneugenic benzimidazoles, other aneugens and other substances in the in vitro micronucleus assay	2013	42
FSA-funded research on the effects of soya phytoestrogens in patients with compensated hypogonadism	2014	10

## Annual Report 2018

FSA-funded research on the effects of soya isoflavones on markers of bone turnover in females in the early menopause	2014	10
FSA-funded research on the effect of soya phytoestrogen supplementation on thyroid status and cardiovascular risk	2014	11
Formaldehyde	2007	182
Evidence for systemic mutagenicity	2007	133
French Maritime Pine bark extract	1998 1999 2000	10 16 19
Fumagillin	2009	141,196
Fumagillin Dicyclohexylamine	2011	41
Fumonisin in maize meal	1993 2003	48 15
Furan	2005	8, 84, 135
Furocoumarins in the diet	1994	25, 39
GADD45a GFP 'Green Screen' assay	2010	42
Gallates	1992	37
Gellan Gum	1993	13
Genetic susceptibility to cancer	2000 1998	110 35
Genotoxic Consequences of Exposure to Mixtures of Food-Derived Chemical Carcinogens	2012	39
Genotoxic alkylating agents	2006	237
Genotoxic carcinogens and DNA repair at low doses	2004	136, 176
Acute T25 – possible approach to potency ranking of single exposure	2006	279
Genotoxicity, evidence for Biological effects of wear debris generated from metal on metal on metal bearing surfaces	2006	232, 241
Genotoxicity in pesticide applicators, biomonitoring studies for	2004	146
Genotoxicity testing and mutagenic Hazard assessment of chemical substances. Consultation on a strategy for	2010	48
Genotoxicity Testing of Impurities	2011	44
Genotoxicity of Nanomaterials	2011 2012	45 36
Genotype and environment interaction on susceptibility to cancer	2001 2002	142 132
Genotypes and chemicals in the environment on the induction of cancer in risk assessment. Interaction between	2010	59
Germ cell mutagenesis adverse outcome pathways consolidated summary of discussions	2015 2016 2017	37 34 42
Glucosamine and hepatotoxicity	2008 2009	20 15, 38
Gluten - timing of introduction into the infant diet	2010 2011	27 11

## Annual Report 2018

Guar gum	1991	14
Guidance Statements	2010	63
on assessment strategies and genotoxicity tests	2010	41
Guidance statements	2011	58
	2012	48
Guidance statement on the human health significance of chemical induced mutagenicity	2017	55
	2013	45, 59
Guidance on a Strategy for Genotoxicity Testing of Chemical Substances	2011	42
Guidance on Mutagenic Hazard Assessment and a Strategy for Genotoxicity Testing of Chemicals with Inadequate Genotoxicity Data	2011	43
Halonitromethanes (HNMs)	2005	85, 116
Health assessment of the exposure of 2 year-olds to chemical substances in consumer products' Danish Environmental Protection Agency (EPA) report on	2010	8
Health effects in populations living close to landfill sites	2000	19
	2001	15
Heat-not-burn tobacco products and their safety. overview of genotoxicity data submitted (confidential)	2017	8, 51
	2017	41
Hemicellulase Enzyme in bread-making	1999	19
from <i>Aspergillus niger</i>	1994	8
Preparations for use in breadmaking	1995	9
	1996	9
Hexachlorobutadiene contamination at Weston Quarries	2000	20
	2003	10
$\alpha$ -, $\beta$ - and $\gamma$ -hexachlorocyclohexanes in the infant diet	2014	12
Hexabromocyclododecanes in infants diet	2015	7
	2016	11
Histamine in food	2016	12
Historical control data in mutagenicity studies	1996	47
Hormesis	2003	196
	2012	38
HSE priority programme	2004	177
Human Health Significance of Chemical Induced Mutagenicity	2011	44
	2012	36
Hydrocarbon propellants	1994	9
Hydrogel filler for breast implants: Further studies	2005	9, 61
Hydrolysed cows' milk formulae: role in influencing the development of atopic outcomes and autoimmune disease	2016	14
Hydroquinone and phenol	1994	20
	1995	34
	2000	60
review of mutagenicity of Aclonifen and risk assessments of its postulated metabolites	2008	262
Hyperactive children's support group	1996	9
Hyperactivity and food additives	2000	27
Additional analyses on research project results	2001	16
Hypospadias and maternal nutrition	1999	19

## Annual Report 2018

Idiopathic Environmental Intolerance: Evidence for a toxicological mechanism	2010 2011	27 13
ICH guidelines: Genotoxicity: A standard battery for genotoxicity testing of pharmaceuticals (S2B) and consideration of the mouse lymphoma assay	1997	75
Consideration of neonatal rodent bioassay	1998	50
Testing for carcinogenicity of pharmaceuticals	1997	112
Idiopathic Environmental Intolerance: Evidence for a toxicological mechanism	2009	36
IGHRC		
paper on uncertainty factors	2001 2002	17 129
guidance document on chemical mixtures	2007	21
guidelines on route-to-route extrapolation of toxicity data when assessing health risks of chemicals	2005	15
IGF-1: Possible carcinogenic hazard to consumers IGF-1 and cancer risk	2012 2013 2017	47 58 55
ILSI/HESI research programme on alternative cancer models: results of Syrian hamster embryo cell transformation assay	2002	87
ILSI/HESI workshop on less-than-lifetime exposure to carcinogens	2012	44
Imidocarb	1992	38, 57
Immobilised lipase from <i>Rhizopus Niveus</i>	1994	9
Impurities	2008	227
in the pesticide 1-methylcyclopropene	2003	191
Insulin-like growth factor-1 (IGF-1) in the diet, The potential carcinogenic risk of	2009	229
<i>In vitro</i> mammalian cell mutation assays	2003	137
<i>In vitro</i> micronucleus test	1994 1996 2004	26 47 144
(IWGT meeting)	2002	88
<i>In vivo</i> gene mutation assays using transgenic animal models	1996	45
<i>In-vivo</i> mutagenicity at high doses, Significance of	2002	89
<i>In vivo</i> PIG-A mutagenicity assay	2010	44
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968-1998	2001	138
Infant feeding and allergy	2013	30
Infant food, metals and other elements in	1999	27
International workshop on the categorisation of mutagens	2001	108
Interaction between genotype and chemicals in the environment on the induction of cancer in risk assessment	2011	53
Interim Guidance on a Strategy for Genotoxicity Testing and Assessment of Impurities	2012	35
Intrahepatic cholangiocarcinoma	2003	192

## Annual Report 2018

Iodine	1992 2000	25 17
in cows' milk	1997 1999 2002 2003	17 20 20 10
in diet of infants and young children	2017	7
Iron, Toxicological aspects of the SACN report on	2009	29
Irritant sprays	2016	14
guidance on submission of papers to COT regarding irritant sprays and information required	2017	28
ISO Water quality standard: Determination of the genotoxicity of water and waste water using the umu test	1997	69
Joint COC/COM symposium on genetic susceptibility to cancer	1998	35
Joint COM/COC on the significance of low level exposures to DNA adduct inducing chemicals	1996	48
Joint meeting of COT/COC/COM on use of genomics and proteomics in toxicology	2001 2002	24, 109, 143 14
Joint meeting of COT/COM on use of target organ mutagenicity assays in carcinogen risk assessment	2005	92, 124
Joint meeting with the Committee on Safety of Medicines on food-drug interactions	2004	23
Joint symposium with COM on use of target organ mutagenicity in carcinogen risk assessment	2004	192
Joint COT/COC/COM review of nanomaterials	2005	86
Joint COT/CSM one day meeting on diet and drug interactions	2005	27
Kava kava		
urgent advice	2002	14
in food products	2005	9
Lactic acid producing cultures	1991	14
Landfill sites	2010	13
and congenital anomalies	1998	13
and adverse birth outcomes	2007	24
Chemical exposure resulting from	2009	36
Health effects of populations living close to,	2000 2001	19 15
Potential exposure to substances from	2008	20
Lead in the infant diet	2013 2016	19 14
Lead ammunition group final report	2015	8
Leukaemia		
Advice on three paediatric cases in Camelford, North Cornwall	1996	57
and drinking water in South West England	1997	105
Lindane	1995	33
Lipophilic shellfish toxin mouse bioassay, atypical results in	2004	8

## Annual Report 2018

Long chain polyunsaturated fatty acid for use in infant formula	1997	19
Longevity of carcinogenicity studies: consideration of a database prepared by the Pesticides Safety Directorate	2000	109
Lowermoor subgroup	2004 2005 2006 2007 2008 2009 2010 2012	15 14 18 23 19 35 25 20
Lung cancer and Environmental Tobacco Smoke (ETS)	1997	88
Lupins	1995	10
Malachite Green	1993 1995 1999 2003	14 12 47 130
and Leucomalachite Green	2004	138, 152, 182
in Farmed fish	1999	23
Malathion	2002 2003	84, 126 132
Male reproductive system, Adverse trends in the development of	2003	21
Potential chemical causes	2004 2006	7, 32 8, 47
Man-made mineral fibres	1994 1996	38 65
Refractory ceramic fibres	1995	68
Marine biotoxins	2005	17
	2006	13, 156
Maternal and infant dietary exposures and risk of development of atopic outcomes and autoimmune disease.	2017	26
Mathematical modelling – Applications in toxicology	1999	27
Measurement of toxins that cause Paralytic Shellfish Poisoning (PSP)	2011	15
Mechanism of carcinogenicity in humans	1995	57
Meglumine	2003 2005	129 87, 119
Mercury in fish and shellfish	2002 2003	17 12
Metals and other elements		
in infant food	1999 2003 2017	27 12 27
in the 2000 Total Diet Study	2003	12
2006 UK Total Diet Study	2008	16, 170



## Annual Report 2018

Methanol - chronic toxicity	2010	28
Methylation, transgenerational effects of	2006	236
Methylcyclopentadienyl manganese tricarbonyl	1995 1999	12 28
1-Methylcyclopropene, Impurities in	2003	191
Methylglyoxal	2009	16, 76
Microbial enzyme preparations (safety assessment of)	1991	17
Milk, Persistent environmental chemicals in human	2009	223
Mineral hydrocarbons	1993	15
Mixtures		
an appraisal of a report on “State of the Art on Mixture Toxicity”	2010	15
Carcinogenicity of	2008 2010	284 57
of food additives (T01040/41), FSA funded research on health effects of	2008	10, 204
of food contaminants and additives	2004	15
consideration of FSA-funded research on joint endocrine effects of multi-component mixtures of food contaminants and additives	2010	16
IGHRC guidance document	2007	21
Mode of Action / Human Relevance Framework	2008	279
Moniliformin in maize and maize products	1998	14
3-Monochloro-propane 1,2-diol (3-MCPD)	1999 2000	48 61, 102
Mouse lymphoma assay, Presentation by Dr Jane Cole	1997	77
Mouse bioassay, atypical results in the lipophilic shellfish toxin mouse bioassay	2004	8
Mouse carcinogenicity bioassay	1997	70, 117
Mouse Spot Test	1992	44
Multi-element survey		
in various items in the diet	1998	15
of wild fungi and blackberries	1999	28
Multiple Chemical Sensitivity	1999 2000	30 21
Multi-strain assays	2009	16
Municipal solid waste incinerators in Great Britain, Cancer incidence near	2000 2008 2011	104 284 54
Mutagenicity		
Comet assay	2006	239, 249
UDS assay	2006	239, 249
Mutagenicity testing strategies	1991 1992	33
Mutagens		
classifications of	1992	43
Thresholds for <i>in vivo</i>	2010	41
Mutational spectra	2014	35

## Annual Report 2018

Mutational signatures associated with tobacco smoking in human cancer- and associated editorial paper.	2017	53
Muta <sup>®</sup> mouse and Big Blue transgenic rodent assay systems	2005	12434
Mycotoxins	1991	31, 48
In cheese	2006	9
Nanomaterial toxicology	2005 2006	16, 65 19
Joint statement of COC/COM/COT, COT addendum	2007	27
Nanomaterial review	2005	86
Nanoparticles used in healthcare and update on nanomaterial technology	2007	9
Nanotechnologies in the food and feed area	2008	11
Natural toxins	1992	44, 59
National Diet and Nutrition Survey	2009	17
National Health And Nutrition Examination Survey(NHANES)	2010	16
Nephropathy observed in a 2-year carcinogenicity study	2008	12
Neurotoxicity, Developmental	2009	14
Newlase analytical method to detect rhizoxin	2000 2002 2004	17 11 10
Nicotine from nicotine patches, Possible nitration of	2002	86
Nickel leaching from kettle elements into boiled water	2003 2006 2007	13 19 9
Nicotine from nicotine patches, Possible nitrosation of	2002	86
Nitrate metabolism in man	1998	16
Nitrosamines: potency ranking in tobacco smoke	1995	71
Nitrous oxide	1995	14
N-Nitroso compounds	1992	59
Non-genotoxic carcinogens, Early identification of	2000	106
Non-Hodgkin's lymphoma	1993 2007 2009	51 185 221
Chemical aetiology	2008	284
Nonivamide (PAVA):		
use as an incapacitant spray	2001 2002 2007 2015	25 18, 85 10 8
new formulation of	2017	28
consideration of an updated statement in the light of new evidence	2004	11, 107
and 2-Chlorobenzylidene malonitrile: combined use	2005 2006 2015	17 7, 21 8
Novel fat	1992	24
for use in confectionery	1992	18
Novel oils for use in infant formulae	1995	14
Nuclear establishments, chemicals used at	1991	35

## Annual Report 2018

Obesogen hypothesis	2013	21
Ochratoxin A	1997 1998	20 17
OECD genotoxicity test guidelines update	2015 2017	40 43
OECD Guidance document for the performance of chronic toxicity and carcinogenicity studies	2009	225
OECD Test Guidelines for carcinogenicity studies, Revision of	2008	282
OECD guidelines; ToxTracker assay, Standard Project Submission form for,	2017	51
Oesophageal cancer	2004	178
Ohmic heating	1991	19
Olestra	1993	35
Olfactory neuroblastomas: possible association in dentists and dental nurses	2003 2004	197 179, 251
Omethoate	1992	38
Openness (see also Committee procedures)	1999 2002 2003	30 20 194
Ontario College of Physicians report	2004	182
Organ mutagenicity data in carcinogen risk assessment	2005	124
Organochlorines and breast cancer	1995 1999 2003 2004	66 62 196 180
Organophosphates	1999 2010	30 40
and human health	2007	10
and human health: outstanding Government funded research	2009	18
Long-term neurological, neuropsychological and psychiatric effects of low-level exposure to organophosphates in adults	2014	13
Organophosphorus esters	1998	17
OST code of practice for scientific advisory committees and committee procedures in light of the Government's response to the BSE enquiry report	2001 2002 2003	14, 139 86, 129 17
Ozone	1999	50
review of animal carcinogenicity data	1999	71
p-53 tumour suppressor gene	1993	39
PAH concentrations in food: interim pragmatic guideline limits for use in emergencies	2001	18
PAHs in shellfish	2001	18
Parachloroaniline	2009	144, 203
Paraffins in food, Chlorinated	2009	13, 111
Paralytic Shellfish Poisoning (PSP)	2006	12, 131
biotoxins	2010	18

## Annual Report 2018

Para occupational exposure to pesticides and health outcomes other than cancer	2011	16
Systematic review of the epidemiological literature on	2010	62
Para-occupational exposure to pesticides and health outcomes	2009	36
Systematic review of the epidemiological literature on	2010	28
Para red		
Mutagenicity of	2005	12
risk assessment	2005	72
Passive smoking	1993	52
Pathway Analysis Software for the interpretation of complex datasets	2009	26
Paternal exposure to chemicals, possibility of paternal exposure inducing cancer in offspring	1991	36
Patulin	1991	49
PAVA (Nonivamide):	2004	95
use as an incapacitant spray	2001 2002 2006 2007 2013 2015	25 18, 85 19 10 14 8
consideration of an updated statement in light of new evidence	2004	11, 107
and 2-chlorobenzlidene malonitrile: combined use	2005 2006 2013 2015	17 7, 21 14 8
PCBs in breast milk	2001	19
Peanut allergy	1996 1997 1998	10 23 18
Peanut avoidance review of the 1998 COT recommendations on	2008	12, 133
Pediatric leukaemia cases in Camelford, North Cornwall	1996	57
People for the Ethical Treatment of Animals “Creative Accounting” Report by	2006	282
Perchloroethylene (see tetrachloroethylene)		
Perfluorooctanoic acid (PFOA)	2005 2006 2009	18, 87, 136 11, 87 27, 49
Perfluorooctane sulfonate (PFOS)  in the infant diet	2005 2006 2009 2014	17, 87, 136 11, 110 27 16
Peripheral blood lymphocytes (PBLs)		

## Annual Report 2018

Background variation in micronuclei (MN) and chromosomal aberrations (CA)	2006	233, 254
Peroxisome proliferators	1992	45
Pesticides, bystander exposure to	2009	8
Pesticides and health outcomes, Para-occupational exposure to	2009	36
Pesticide applicators, biomonitoring studies for genotoxicity in	2004 2005	146 82, 93
Phenol	2003 2008	132 231
Update statement(2008) on mutagenicity of tolerable daily intake (oral)	2008 2002	252 15
2-Phenylphenol	1992 1997 2003	39 64 133
Phosphate and the calcium-parathyroid hormone axis	2004 2005	11, 54 19
Phosphine	2001	103
and metal phosphides	1997	65
Phosphorus, parathyroid hormone and bone health	2003	21
Phthalates in infant formulae	1996	10
Phytoestrogens research programme	2011 2012	27 14
Phytoestrogens in soya-based infant formulae	1998 1999	18 35
and health, report	2002 2003	20 17
Platinum-based fuel catalyst for diesel fuel	1996	12
Polybrominated biphenyls (PBBs) in diet of infants	2015	9
Polybrominated biphenyls (PBBs) in diet of infants and 1 – 5 year old children	2015	10
Polybrominated diphenylethers (PBDEs) in the diet of infants and young children	2016 2017	16 11
addendum		
Polychlorinated biphenyls (PCBs)	1994 1997	21, 37 23
Effects on play behaviour	2002	17
PCDDs, PCDFs and PCBs in marine fish and fish products	1999	31
Polychlorinated naphthalenes in food	2009	28,87
Polycyclic aromatic hydrocarbons	1994 1995 1996	19, 34 32 67
Advice on dibenzo(a,l)pyrene	2002	127
In air pollution	2003 2004	135, 192 183
In the 2000 Total Diet Study	2002	16
Pragmatic guideline limits for use in emergencies	2000	27

## Annual Report 2018

Polyurethane	1991	46
Polyurethane coated breast implants	1994 2012	36 44
Potassium and sodium ferrocyanides	1994	10
Potassium salt replacers in vulnerable groups	2013	30
Potassium-based replacements for sodium chloride and sodium-based additives.	2017	13
Potatoes genetically modified to produce Galanthus nivalis Lectin	1999	34
Potential role of oxidative damage in alcohol's mutagenic and carcinogenic mode of action	2015	35
Pregnancy, Vitamin E in	2009	31
Presentation on initial preliminary results of meta-analysis of alcohol and breast cancer	2001	142
Presentation to COM on:		
<i>Which mammalian cell tests best complement the Ames test in terms of detecting rodent carcinogens and in vivo genotoxins.</i> ' - Professor David Kirkland	2010	45
<i>Cytokinesis-block (CBMN) assay for the measurement and comparison of Carcinogenic and in vivo genotoxicity potency estimates.</i> ' - Dr Nabil Hajji	2010	46
Prioritisation of carcinogenic chemicals	1994	41
Propoxur	1991	47
Propylene carbonate	1992	26
Proquinazid	2005	87, 138
Mutagenicity and Carcinogenicity of	2005	155
Prostate cancer	2002 2003 2004	134 197 185, 254
Phthalates – data from the Total Diet Study. Dietary exposure to	2010	27
Pyrolizidine alkaloids in food	2007 2008	24 13, 110, 280
Ranking of carcinogens: comparison of method using some air pollutants	2001	140
Quantification of risk associated with carcinogenic air pollutants	2002	128
Quantitative structure-activity relationships (QSAR)	2007	182
Quantitative approaches to the assessment of genotoxicity data.	2016 2017	37 41
REACH (Registration, Evaluation and Authorisation of CHemicals)		
Technical guidance for derivation of DNELs and risk characterisation of non-threshold effects in the context of	2007	21, 184
RCEP		
study of long term effects of chemicals	2001	20
crop spraying and the health of residents and bystanders	2006	13, 213, 283

## Annual Report 2018

Reassessment of the toxicological testing of tobacco	2004	19, 107
Reassessment of toxicology of tobacco products	2004	142, 186
Refractory ceramic fibres	1995	68
Relative Vulnerability of Children to Asbestos	2012	46
Report by the EU Scientific Committees on Consumer Products, on Health and Environmental Risks, and on Emerging and Newly-Identified Risks on 'Risk assessment methodologies and approaches for mutagenic and carcinogenic substances'	2008	280
Report on phytoestrogens and health	2002	20
Reproductive effects of caffeine	2001 2007 2008	22 24 14
Reproductive outcomes, chlorinated drinking water and	1998 2001 2004	8 23 8, 46
Research		
and surveys, Food Standards Agency funded	2000	18
priorities and strategy, Department of Health	1996	9, 44, 75
Project(T07040) investigating the effect of mixtures on certain food colours and a preservative on behaviour in children	2007	49
Restriction report: proposal for a restriction: bis(2-ethylhexyl)phthalate (DEHP), benzyl butyl phthalate (BBP), dibutyl phthalate (DBP) and diisobutyl phthalate (DiBP)	2011	18
Review of toxicogenomics, COT/COC/COM	2004	144
Review of the mutagenicity of alcohol	2015	35
Review of current approaches to germ cell mutagenicity testing	2013	45
Rhizoxin – newlase analytical method to detect	2000 2002 2004	17 11 10
Risk assessment of carcinogens, Revised guidance	2003	197
COC guidance on a strategy for the	2004	188
Risk assessment of <i>in vivo</i> mutagens (and genotoxic mutagens)	2001	107
Risk Assessment of Mixtures of Pesticides (and similar substances)	2000 2002	25 19
Risks arising from the infant diet and the development of atopic and autoimmune disease	2012	21
'Risk assessment methodologies and approaches for mutagenic and carcinogenic substances', Preliminary Report by the EU Scientific Committees on Consumer Products, on Health and Environmental Risks, and on Emerging and Newly-Identified Risks on	2008	280
Risk assessment strategies Guidelines for exposure assessment practice for human health	2003	19

## Annual Report 2018

Mixtures of food contaminants and additives	2004	15
Physiologically-based pharmacokinetic modelling	2003	19
RCEP study on pesticides and bystander exposure	2004	18
Reassessment of the toxicological testing of tobacco	2004	19
Royal society study on nanoscience and nanotechnology	2004	20
Uncertainty factors: their use in human health risk assessment by UK government	2003	20
Uncertainty in chemical exposure assessment	2004	21
Use of toxicogenomics in toxicology (update on statement published in 2002).	2004	22
Risk communication	2007	182
Risks of chemical toxicity and allergic disease in relation to infant diet	2012	14
Risk procedures used by the Government's Advisory Committees dealing with food safety	2000	22, 110
Risks associated with exposure to low levels of air pollution	2003	193
RNA Interference	2005	16
RNA related effects as a mechanism of carcinogenicity	2009	228
Royal society study on nanoscience and nanotechnology	2004	20
SACN report on Iron and Health,	2009	226
Toxicological aspects	2009	29
SACN Review of Vitamin D	2011 2012 2013	28 21 31
SAHSU study, Chlorination disinfection by-products and risk of congenital anomalies in England and Wales	2008	9 27
Salmonella assay, Use of	1991	35
SCF Guidelines on the Assessment of Novel Foods	1996	13
SCCNFP testing strategy for cosmetic ingredients	2004	144
Science Strategy 2005-2010: FSA Draft	2005	14
Sellafield	1991	35
Seaweed, arsenic in. -Urgent advice	2004	13,122
Sensible drinking message, Evaluation of	1995	58
SHE cell transformation assay	1996	46
Shellfish		
poisoning, amnesic	2001	7
PAHs in,	2001	18
Atypical results in the lipophilic shellfish toxin mouse bioassay	2004	8
Short and long chain triacyl glycerol molecules (Salatrim)	1997 1999	39 36
Short-term carcinogenicity tests		
ILSI/HESI research programme on alternative cancer models	1997 1999	114 73
using transgenic animals	2002	131
Significance of environmental mutagenesis	2004	141
Significance of in vivo mutagenicity at high doses	2003	139



## Annual Report 2018

Single cell protein	1996	14
Single or short term exposure to carcinogens	2005	140
Skin sensitisation from exposure to pesticide	2015	12
Sodium benzoate and potassium sorbate	2007	134
Soil, Contaminants in	2001	10
Soluble fibre derived from guar gum	1996 1997	15 46
Soy phytoestrogens in the infant diet	2013	23, 31
Soya consumption and thyroid status	2015	13
Squamous cell carcinoma and alcohol consumption: review of the quantitative relationship between	2005	139
Statement of consumption of alcoholic beverages and risk of cancer	2015	44
Statement on photogenotoxicity testing	2013	43
Statement on the use of mutation spectra in genetic toxicology	2015	35
Statement on the mutagenicity of alcohol(ethanol) and its metabolite acetaldehyde	2015	35
Sterigmatocystin	1998	19
Strategy for investigating germ cell mutagens	2003	138
Sucralose	1993 1994 2000	34 24 23
Sudan I found in chilli powder	2003	16
Sulphur dioxide	1991	19, 30
Surveys: guidelines for project officers	2001	22
Swimming pool disinfection by-products and genotoxicity assessment	2013	44
Systematic review of the epidemiological literature on para-occupational exposure to pesticides and cancer	2011	55
Terephthalic acid	2001 2003 2007 2008	105 14 135 16
and isophthalic acids in food	2000	24
multigenerational reproduction study additional histopathological examinations	2005	10
The role of miRNA related effects and chemicals on cancer	2011	56
Update statement on the Toxicology of	2008	21
T25 to estimate carcinogenic potency	1995	72
Test strategies and evaluations	1993 1994 1995 1996 1997 1998 1999 2000	39 25 37 44, 75 75, 112 34, 50 51, 72 63

	2001	107
	2002	87, 129
	2003	137 to 139, 194 to 196 143 to 146
	2004	188 to 190
	2006	240
	2007	137
	2008	234
Testicular cancer	2006	285
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)	1993	49
	1995	15, 64
	1998	45
	1999	49
	2001	136
Tetrabromobisphenol A review of toxicological data in the infant diet	2004	12
	2004	62
	2014	19
Tetrachloroethylene	1993	21, 48
	1996	37, 68
	1997	47
Thalidomide	1997	62
The carcinogenicity of carbon nanotubes	2011	58
Thiabendazole	1991	20
	1995	20
	1996	40
	1997	50
Thiamphenicol	1992	26
Threshold for benzene induced carcinogenicity, Consideration of evidence for	1998	32
Thresholds for aneuploidy inducing chemicals	1995	37
	1996	42
Thresholds for <i>in vivo</i> mutagens	2009	151
Tobacco induced lung carcinogenesis: the importance of p53 mutations	2001	107
Tobacco products	2008	14
	2009	145
Carcinogenicity testing of	2009	219
reassessment of the toxicological testing of	2004	19, 107
reassessment of the toxicology of	2004	142, 186
Toltrazuril	1992	57
Total Diet Study, Cadmium in the 2006	2009	12
Toxic equivalency factors for dioxin analogues	1998	19
Toxicity of chemicals in the infant diet; and the diet of young children aged 1 to 5 years	2012	22
	2013	31
	2016	22
	2017	27
Toxicogenomics	2007	137, 185
	2008	235

## Annual Report 2018

	2009	152
as a tool for identifying genotoxic carcinogens	2013	46
use of in toxicology (update on statement published in 2002)	2004	22, 112
COT/COC/COM review of	2004	144
in toxicology – design, analysis and statistical issues	2010	29
Toxicological aspects of the SACN report on Iron	2009	29
Toxicological evaluation of chemical analyses carried out as part of a pilot study for a breast milk archive	2004	14, 70
Toxicogenomics data in risk assessment	2012	16
Transgenerational Epigenetics, Workshop on	2008	19, 36
Transgenic animal models, Use in short terms tests for carcinogenicity	2001	142
Transgenic mouse models	1997	114
Trichloroethylene	1996	39, 71
Trihalomethanes in drinking water	1994 1995	22, 32, 69 35
Tryptophan and eosinophilia-myalgia syndrome	2003 2004	21 12, 83
Tryptophan in food		
responses to consultation on revision of Regulations	2005	11
Type I caramel	1991	30
Unlicensed traditional remedies	1994	10
Uncertainty factors, IGHRC paper on	2001 2002	17 129
Uncertainty in chemical exposure assessment	2004	21
Uranium levels in water used to re-constitute infant formula	2005 2006	18 14, 196
Use of toxicogenomics in toxicology (update on statement published in 2002).	2004	22, 112
Use of target organ mutagenicity data in carcinogen risk assessment	2005	124
Use of Quantitative Structure Activity Relationships (QSARs) for Mutagenicity	2011	44
Validation of short-term carcinogenicity tests using transgenic animals, Presentation on	1999	73
Variability and Uncertainty in Toxicology – working group	2004 2005 2006 2007	15, 18 14 19 23
Vitamin A in the infant diet addendum	2013 2017	24 15
Vitamin D, adverse effects of high levels	2014	6
Vitamin E in pregnancy	2009	31
Vitamin E and prostate cancer statement	2012 2013 2015	47 57 42
Vitamins and minerals		
Ad hoc expert group (EVM)	1997	6

## Annual Report 2018

European Commission document on establishing maximum and minimum levels in dietary supplements and fortified foods	2006	15
Waste and Resources Action Programme (WRAP)	2009 2010 2013	37 29 26
Wild fungi and blackberries, Multielement survey of	1999	28
Working Group: COT/COC Subgroup on synthesising epidemiological evidence	2017	24, 54
Working Group: COT/SACN Subgroup on the timing of introduction of allergenic foods into the infant diet.	2017	24
Working Group on the review of epidemiological literature on organophosphates and health outcomes relating to the nervous system	2012	19
Working Group on Variability and Uncertainty in Toxicology	2004 2005 2006 2007	15, 18 14 19 23
Workshop on Bystander Risk Assessment Working Group (BRAWG)	2011	26
Transgenerational Epigenetics	2008	19, 36
21 <sup>st</sup> Century Toxicology	2009	35
expression of uncertainty	2010	26
WRAP risk assessment on anaerobic digestates	2011	20
Xylanase preparation from <i>Aspergillus niger</i>	2001	13
Zearalenone	1998	29
Zebrafish	2014	44

## ANNEX 7 – Previous Publications

Publications produced by the Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment

1991 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. HMSO ISBN 0 11 321529-0 Price £9.50.

1992 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. HMSO ISBN 0 11 321604-1 Price £11.70.

1993 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. HMSO ISBN 0 11 321808-7 Price £11.95.

1994 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. HMSO ISBN 0 11 321912-1 Price £12.50.

1995 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. HMSO ISBN 0 11 321988-1 Price £18.50.

1996 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. The Stationery Office ISBN 0 11 322115-0 Price £19.50.

1997 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Department of Health.\*

1998 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Department of Health\*.

1999 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Department of Health\*.

2000 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Department of Health.\*

2001 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, FSA/0681/0802.\*\*

2002 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, FSA/0838/0803.\*\*

## Annual Report 2018

2003 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, FSA/0900/0504.\*\*

2004 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, FSA/0992/0804.\*\*

2005 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, FSA/1098/0906.\*\*

2006 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, FSA/1184/0707\*\*

2007 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, FSA/1260/0608\*\*

2008 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, FSA/1410/0709\*\*

2009 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, July 2010\*\*

2010 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, June 2011\*\*

2011 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, July 2012

2012 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, April 2014

2013 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, March 2015.

2014 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, November 2015.

## Annual Report 2018

2015 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, July 2016.

2016 Annual Report of Committees on Toxicity, Mutagenicity and Carcinogenicity of Chemicals in Food, Consumer Products and the Environment. Food Standards Agency/Department of Health, August 2017.

Guidelines for the Testing of Chemicals for Toxicity DHSS Report on Health and Social Subjects 27 HMSO ISBN 0 11 320815 4 Price £4.30.

Guidelines for the Evaluation of Chemicals for Carcinogenicity DH Report on Health and Social Subjects 42 HMSO ISBN 0 11 321453 7 Price £7.30.

Guidelines for the Testing of Chemicals for Mutagenicity DH Report on Health and Social Subjects 35 HMSO ISBN 0 11 321222 4 Price £6.80.

Guidelines for the Preparation of Summaries of Data on Chemicals in Food, Consumer Products and the Environment submitted to DHSS Report on Health and Social Subjects 30 HMSO ISBN 0 11 321063 9 Price £2.70.

Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment: Peanut Allergy, Department of Health (1998)\*\*

Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment: Organophosphates, Department of Health (1998)\*\*

Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment: Adverse Reactions to Food and Food Ingredients, Food Standards Agency (2000)\*\*

Guidance on a Strategy for testing of chemicals for Mutagenicity. Department of Health (2000)\*

Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment: Risk Assessment of Mixtures of Pesticides and Similar Substances, Food Standards Agency, FSA/0691/0902 (2002).\*\*

Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment: Phytoestrogens and Health, Food Standards Agency, FSA/0826/0503 (2002).\*\*

Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment: Variability and Uncertainty in Toxicology of Chemicals in Food, Consumer Products and the Environment, FSA/1150/0307 (2007).\*\*

Guidance on a Strategy for the Risk Assessment of Chemical Carcinogens. Department of Health (2004)+

\*Available on the COM website at:

<https://www.gov.uk/government/organisations/committee-on-mutagenicity-of-chemicals-in-food-consumer-products-and-the-environment>

## Annual Report 2018

\*\* Available on the COT archive at:

<http://tna.europarchive.org/20130802141804/http://cot.food.gov.uk/cotstatements/>

+ Available on the COC website at

<https://www.gov.uk/government/groups/committee-on-carcinogenicity-of-chemicals-in-food-consumer-products-and-the-environment-coc>

++ <http://cot.food.gov.uk/cotreports/>